Page last updated: 2024-12-06

adapalene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Adapalene is a synthetic retinoid that is used topically to treat acne. It is a derivative of vitamin A and works by reducing the production of sebum (oil) and by preventing the formation of comedones (blackheads and whiteheads). Adapalene is typically applied to the skin once a day. It is available over the counter (OTC) and by prescription. It is known to be effective in treating mild to moderate acne. It is also being studied for its potential in treating other skin conditions, such as psoriasis and rosacea. The synthesis of adapalene starts with a condensation reaction between an aromatic aldehyde and a ketone. The resulting product is then cyclized and functionalized to give adapalene.'

Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID60164
CHEMBL ID1265
CHEMBL ID4303650
CHEBI ID31174
SCHEMBL ID2747
MeSH IDM0175560

Synonyms (131)

Synonym
AC-1974
BIDD:GT0264
bdbm50048280
AB01274764-01
adapaleno
adaferin
6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid
CHEBI:31174 ,
adapalenum
differine
MLS000759463
smr000466349
adapalene
6-(3-(1-adamantyl)-4-methoxyphenyl)-2-naphthoic acid
DB00210
adapalene (jan/usp/inn)
differin (tn)
106685-40-9
D01112
NCGC00164617-01
c28h28o3
adapalenum [inn-latin]
cd-271 ,
differin
cd 271
2-naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo(3.3.1.1(sup 3,7))dec-1-ylphenyl)-
adapaleno [inn-spanish]
cd271
CHEMBL1265 ,
6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
AKOS005145841
6-[3-(1-adamantyl)-4-methoxy-phenyl]naphthalene-2-carboxylic acid;adapalene
A801483
NCGC00164617-02
HMS3264F15
cas-106685-40-9
dtxcid3026481
dtxsid5046481 ,
tox21_112236
6-(3-(adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
BCP9000231
adapalene [usan:inn:ban]
1l4806j2qf ,
differin gel
differin gel 0.1%
adapalen
unii-1l4806j2qf
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
6-(4-methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid
FT-0631040
NCGC00164617-05
AB13763
S1276
AKOS015895391
BRD-K33127281-001-01-5
gtpl5429
6-[3-(adamantan-1-yl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
adapalene [inn]
adapalene [usp-rs]
epiduo component adapalene
adapalene [usp monograph]
adapalene [mart.]
adapalene component of epiduo
adapalene [vandf]
idp-126 component adapalene
adapalene [who-dd]
adapalene [ep monograph]
2-naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo(3.3.1.(sup 13,7))dec-1-ylphenyl)-
adapalene [orange book]
adapalene [usan]
adapalene [mi]
adapalene [jan]
CCG-213060
CCG-221237
HY-B0091
CS-1789
smr002529673
MLS006010036
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalene-carboxylic acid
A2549
SCHEMBL2747
tox21_112236_1
NCGC00164617-04
KS-1196 ,
AB01274764-02
6-[3-(1-adamantyl)-4-methoxy-phenyl]naphthalene-2-carboxylic acid
F2173-0588
6-(3-((3r,5r,7r)-adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
AB01274764_03
AB01274764_04
mfcd03106112
6-[4-methoxy-3-(tricyclo[3.3.1.1~3,7~]dec-1-yl)phenyl]naphthalene-2-carboxylic acid
STL453114
adapalene, >=98% (hplc)
SR-01000942194-2
sr-01000942194
adapalene, united states pharmacopeia (usp) reference standard
HMS3654F11
adapalene for peak identification, european pharmacopoeia (ep) reference standard
adapalene, pharmaceutical secondary standard; certified reference material
adapalene, european pharmacopoeia (ep) reference standard
HMS3715H16
SW219282-1
adapalene; 6-(4-methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)naphthalene-2-carboxylic acid
Q352348
BCP02081
SY009767
CHEMBL4303650
6-(3-(adamantan-1-yl)-4-methoxyphenyl)-2-naphthoicacid
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoicacid
adapalene 100 microg/ml in acetonitrile:dimethylsulfoxide
adapalene- bio-x
BA164138
PD119179
adapalene topical solution
adapaleno (inn-spanish)
adapalene (mart.)
effaclar
adapalene (usp-rs)
proactiv md adapaleneacne treatment
adapalene (usp monograph)
d10ad03
adapalenum (inn-latin)
proactiv md adapalene
6-(4-methoxy-3-tricyclo(3.3.1.13,7)dec-1-ylphenyl)-2-naphthalenecarboxylic acid
6-(4-methoxy-3-(tricyclo(3.3.1.13,7)dec-1-yl)phenyl)naphthalene-2-carboxylic acid
curist acne relief
adapalene gel usp, 0.3%
adapalene (ep monograph)
EN300-19997240

Research Excerpts

Overview

Adapalene 0.1% Gel is a safe and effective medication for the treatment of acne in a non-prescription environment. It is a third-generation retinoid and is used as first-line treatment of moderate acne.

ExcerptReferenceRelevance
"Adapalene 0.1% Gel is a safe and effective medication for the treatment of acne in a non-prescription environment."( Safe Use of Adapalene 0.1 % Gel in a non-Prescription Environment.
Griffin, S; Mallavalli, S; Meckfessel, M; Wagner, N; Weiss, J, 2021
)
1.72
"Adapalene is a third-generation retinoid and is used as first-line treatment of moderate acne."( AbobotulinumtoxinA improves skin properties and sebum quality in the rhino mouse.
Albinet, V; Chusseau, M; Lacoste, E; Maignel, J, 2023
)
1.63
"Adapalene is a good choice in the treatment of acne with fewer side effects and high effectiveness."( Increase adapalene delivery using chemical and herbal enhancers.
Emam, M; Mohammad Soleymani, S; Salimi, A, 2021
)
1.76
"Adapalene (ADAP) is an important drug widely used in the topical treatment of acne. "( Adapalene-loaded poly(ε-caprolactone) microparticles: Physicochemical characterization and in vitro penetration by photoacoustic spectroscopy.
Barboza, FM; Dias, DT; Dos Anjos Camargo, G; Farago, PV; Lyra, A; Macenhan, WR; Nadal, JM; Novatski, A; Padilha de Paula, J; Roik, JR; Somer, A, 2019
)
3.4
"Adapalene (ADA) is a second generation retinoid effective in treating various dermatologic disorders such as Acne vulgaris with a few noticeable dose-mediated side effects."( Adapalene loaded solid lipid nanoparticles gel: an effective approach for acne treatment.
Agarwal, A; Agrawal, GP; Agrawal, H; Garg, NK; Jain, A; Jain, AK; Jain, RK; Jain, SA; Tyagi, RK, 2014
)
2.57
"Adapalene is a widely used topical anti-acne drug; however, it has many side effects. "( Intradermal and follicular delivery of adapalene liposomes.
Banga, AK; Kumar, V, 2016
)
2.15
"Adapalene is a more stable molecule than tretinoin."( A review of adapalene in the treatment of acne vulgaris.
Feldman, SR; Irby, CE; Yentzer, BA, 2008
)
1.45
"Adapalene is a naphthoic acid derivative showing some pharmacological activities similar to the regular retinoids."( Spotlight on adapalene.
Paquet, P; Piérard, GE; Piérard-Franchimont, C; Quatresooz, P, 2009
)
1.44
"Adapalene gel 0.1% is an efficacious treatment for acne vulgaris in Asians. "( Adjunctive usage of a non-comedogenic moisturizer with adapalene gel 0.1% improves local tolerance: a randomized, investigator-blinded, split-face study in healthy Asian subjects.
Chan, R; Kerrouche, N; Leow, YH; Matsunaga, K; Paliargues, F, 2013
)
2.08
"Adapalene gel is a tretinoin derivative and has a lower incidence of irritation compared with other topical retinoid products."( Roles of adapalene in the treatment of pityriasis versicolor.
Ren, XK; Shi, TW; Tang, YB; Yu, HX, 2012
)
1.52
"Adapalene is a topical retinoid analog that has demonstrated efficacy in the reduction of noninflammatory and inflammatory lesions, along with excellent cutaneous tolerability."( Efficacy and cutaneous safety of adapalene in black patients versus white patients with acne vulgaris.
Czernielewski, J; Mizzi, F; Poncet, M, 2002
)
1.32
"Adapalene is a synthetic retinoid with an established clinical efficacy against acne and good local tolerability. "( Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial.
Goldfarb, MT; Griffiths, CE; Hamilton, TA; Kang, S; Metz, RD; Voorhees, JJ; Weiss, JS, 2003
)
2.12
"Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris. "( Adapalene: a review of its use in the treatment of acne vulgaris.
Noble, S; Scott, LJ; Waugh, J, 2004
)
3.21
"Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris. "( Spotlight on adapalene in acne vulgaris.
Noble, S; Scott, LJ; Waugh, J, 2004
)
2.14
"Adapalene is an addition to the arsenal of topical retinoids."( Topical tretinoin or adapalene in acne vulgaris: an overview.
Jain, S, 2004
)
1.36
"Adapalene acts as a penetration enhancer and increases the penetration of topical clindamycin phosphate."( Adapalene pretreatment increases follicular penetration of clindamycin: in vitro and in vivo studies.
Ahmed, FJ; Jain, GK,
)
2.3
"Adapalene is a novel chemical entity which, in terms of pharmacology, behaves similar to tretinoin, but is chemically and photochemically stable. "( Adapalene, a new chemical entity with retinoid activity.
Bernard, BA, 1993
)
3.17
"Adapalene is a new synthetic retinoid analogue developed for the topical treatment of acne vulgaris."( A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial.
Baker, M; Chalker, DK; Czernielewski, J; Ellis, CN; Greenspan, A; Kantor, I; Katz, HI; Millikan, LE; Shalita, A; Swinehart, T; Swinyer, L; Weiss, JS; Whitmore, C, 1996
)
2
"Adapalene is a new chemical entity with retinoid activity."( [Comparative study of the efficacy and tolerability of 0.1 and 0.03 p.100 adapalene gel and 0.025 p.100 tretinoin gel in the treatment of acne].
Alirezai, M; Czernielewski, J; Jablonska, S; Meynadier, J; Verschoore, M, 1996
)
1.97
"Adapalene is a stable naphthoic acid derivative with potent retinoid pharmacology, controlling cell proliferation and differentiation. "( Pharmacology and chemistry of adapalene.
Michel, S; Shroot, B, 1997
)
2.03
"Adapalene is a new naphthoic acid derivative with potent retinoid and antiinflammatory properties, developed for the topical treatment of acne vulgaris."( Adapalene 0.1% gel has low skin-irritation potential.
Clucas, A; Czernielewski, J; Poncet, M; Sorba, V; Verschoore, M, 1997
)
3.18
"Adapalene is a new naphthoic acid derivative developed for the topical treatment of acne vulgaris."( Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients.
Caron, D; Clucas, A; Kerrouche, N; Sorba, V, 1997
)
2.04
"Adapalene is a new naphthoic acid derivative developed for the topical treatment of acne vulgaris."( Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients.
Baker, M; Clucas, A; Czernielewski, J; Poncet, M; Sorba, V; Verschoore, M, 1997
)
3.18
"Adapalene is a new chemical entity that exhibits tretinoin-like activities in the terminal differentiation process."( Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.
Alirezai, M; Caputo, R; Chalker, DK; Cunliffe, WJ; Czernielewski, J; Dreno, B; Ellis, CN; Förström, L; Greenspan, A; Heenen, M; Jablonska, S; Kantor, I; Katz, HI; Meynadier, J; Millikan, LE; Orfanos, CE; Privat, Y; Robledo Aguilar, A; Shalita, A; Swinehart, JM; Swinyer, L; Verschoore, M; Weiss, JS; Whitmore, C, 1997
)
2
"Adapalene 0.1% gel is a safe and effective treatment of acne vulgaris."( Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.
Alirezai, M; Caputo, R; Chalker, DK; Cunliffe, WJ; Czernielewski, J; Dreno, B; Ellis, CN; Förström, L; Greenspan, A; Heenen, M; Jablonska, S; Kantor, I; Katz, HI; Meynadier, J; Millikan, LE; Orfanos, CE; Privat, Y; Robledo Aguilar, A; Shalita, A; Swinehart, JM; Swinyer, L; Verschoore, M; Weiss, JS; Whitmore, C, 1997
)
2
"Adapalene is a stable naphthoic acid derivative that displays a strong retinoid agonist pharmacology. "( A new concept of drug delivery for acne.
Allec, J; Chatelus, A; Michel, S; Shroot, B; Wagner, N, 1998
)
1.74
"Adapalene is a new topical retinoid derived from naphthoic acid with a selective effect on the epidermis. "( [Pharma-Clinics. The drug of the month. Adapalene (Differin gel)].
Bonardeaux, C; de la Brassinne, M, 1998
)
2.01
"Adapalene is a useful new agent because of its tolerability and stability. "( Adapalene: an update on newer comparative studies between the various retinoids.
Millikan, LE, 2000
)
3.19
"Adapalene is a naphthoic acid derivative with retinoid activity that is effective in the treatment of mild to moderate acne vulgaris."( Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel.
Baker, M; Clucas, A; Mesaros, S; Poncet, M; Queille-Roussel, C; Soloff, AM, 2001
)
2
"Adapalene gel 0.1% is an effective, well-tolerated topical therapy for black patients. "( Adapalene in the treatment of African patients.
Jacyk, WK, 2001
)
3.2
"Adapalene is a new naphthoic acid derivative with strong retinoid agonistic pharmacological properties. "( Comparison of the effects of tretinoin, adapalene and collagenase in an experimental model of wound healing.
Agalar, F; Altuntas, I; Basak, K; Basak, PY; Eroglu, E; Sutcu, R,
)
1.84

Effects

Adapalene has a large and reassuring MOS making it suitable for OTC use. It has a rapid onset of action and a particularly favourable tolerability profile compared with other retinoids.

Adapalene has been approved by FDA for the treatment of acne, pimples and pustules. It may also contribute to the adjunctive therapy for advanced stages of liver and colorectal cancers.

ExcerptReferenceRelevance
"Adapalene has a large and reassuring MOS making it suitable for OTC use. "( Safe Use of Adapalene 0.1 % Gel in a non-Prescription Environment.
Griffin, S; Mallavalli, S; Meckfessel, M; Wagner, N; Weiss, J, 2021
)
2.44
"Adapalene has a rapid onset of action and a particularly favourable tolerability profile compared with other retinoids."( Adapalene: a review of its use in the treatment of acne vulgaris.
Noble, S; Scott, LJ; Waugh, J, 2004
)
2.49
"Adapalene has a rapid onset of action and a particularly favorable tolerability profile compared with other retinoids."( Spotlight on adapalene in acne vulgaris.
Noble, S; Scott, LJ; Waugh, J, 2004
)
1.41
"Adapalene has a large and reassuring MOS making it suitable for OTC use. "( Safe Use of Adapalene 0.1 % Gel in a non-Prescription Environment.
Griffin, S; Mallavalli, S; Meckfessel, M; Wagner, N; Weiss, J, 2021
)
2.44
"Adapalene has been approved by FDA for the treatment of acne, pimples and pustules, and it may also contribute to the adjunctive therapy for advanced stages of liver and colorectal cancers."( Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1.
Chen, L; Li, H; Li, K; Luan, S; Wang, Q; Yang, K; Zhang, Q; Zheng, M, 2019
)
2.68
"Adapalene has been previously evaluated as a treatment for actinic keratosis (AK) and solar lentigines and shown to improve signs of photoaging."( Comparable efficacy of adapalene 0.3% gel and tretinoin 0.05% cream as treatment for cutaneous photoaging.
Almeida, LMC; Bagatin, E; Gonçalves, HS; Miot, HA; Sato, M, 2018
)
2.23
"Adapalene has a rapid onset of action and a particularly favourable tolerability profile compared with other retinoids."( Adapalene: a review of its use in the treatment of acne vulgaris.
Noble, S; Scott, LJ; Waugh, J, 2004
)
2.49
"Adapalene has a rapid onset of action and a particularly favorable tolerability profile compared with other retinoids."( Spotlight on adapalene in acne vulgaris.
Noble, S; Scott, LJ; Waugh, J, 2004
)
1.41
"Adapalene gel 0.1% has tolerability superior to both tazarotene cream 0.05% and tretinoin microsphere 0.04% when used in topical combination therapy. "( Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies.
Arsonnaud, S; Dosik, JS; Gilbert, RD,
)
1.57
"Adapalene has comedolytic activity in the topical rhino mouse model."( Adapalene, a new chemical entity with retinoid activity.
Bernard, BA, 1993
)
2.45
"Adapalene cream 0.1% has proven to be significantly more effective than vehicle, with response rates comparable to those observed with the gel and solution."( Pivotal clinical trials of adapalene in the treatment of acne.
Millikan, LE, 2001
)
1.33

Actions

ExcerptReferenceRelevance
"Both adapalene and tretinoin produce dramatic reductions in total, inflammatory and non-inflammatory lesion counts, in the range of 69-74% on average."( A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China.
Li, GQ; Tu, P; Wong, WZ; Zheng, J; Zhu, XJ, 2001
)
1.11

Treatment

Adapalene is used for treatment of acne vulgaris, a common dermatological disease. Treatment produced rapid resolution of inflammatory and non-inflammatory lesions, and inhibited formation of new lesions.

ExcerptReferenceRelevance
"Adapalene is used for treatment of acne vulgaris, a common dermatological disease. "( A topical gel of tea tree oil nanoemulsion containing adapalene versus adapalene marketed gel in patients with acne vulgaris: a randomized clinical trial.
Amani, A; Ehsani, A; Eslami Farsani, V; Jafarzadeh Kohneloo, A; Mehdizade Rayeni, N; Moghimi, HR; Najafi-Taher, R, 2022
)
2.41
"Adapalene treatment was associated with a greater lesion count than placebo at 4 weeks, although the difference was not statistically significant (mean, 12.6 vs."( Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Chayahara, N; Doi, H; Fujishima, Y; Fukunaga, A; Kawaguchi, A; Kiyota, N; Kobayashi, K; Marugami, N; Minami, H; Mizuta, N; Mukohara, T; Nakata, K; Nishigori, C; Nishimura, Y; Tachihara, M; Takenaka, K; Tobimatsu, K; Toyoda, M; Washio, K; Yamamoto, M, 2019
)
2.68
"Adapalene-treated subjects achieved similar percent reductions in total lesion counts at week 12 compared to subjects receiving switch therapy, demonstrating the noninferiority of adapalene gel treatment (median difference: -3.57%; lower confidence limit [LCL]: -11.25)."( Is switching retinoids a sound strategy for the treatment of acne vulgaris?
Colón, LE; Gold, LS; Gottschalk, RW; Johnson, LA, 2008
)
1.07
"Adapalene treatment produced rapid resolution of inflammatory and non-inflammatory lesions, and inhibited formation of new lesions."( New photographic techniques for clinical evaluation of acne.
Kligman, A; Rizova, E, 2001
)
1.03

Toxicity

No drug was detected in blood/liver which in addition to an absence of any adverse effect on liver and enzymes. Adapalene was well tolerated, with adverse events that were mostly mild-to-moderate and transient in nature.

ExcerptReferenceRelevance
"1% gel is a safe and effective treatment of acne vulgaris."( Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.
Alirezai, M; Caputo, R; Chalker, DK; Cunliffe, WJ; Czernielewski, J; Dreno, B; Ellis, CN; Förström, L; Greenspan, A; Heenen, M; Jablonska, S; Kantor, I; Katz, HI; Meynadier, J; Millikan, LE; Orfanos, CE; Privat, Y; Robledo Aguilar, A; Shalita, A; Swinehart, JM; Swinyer, L; Verschoore, M; Weiss, JS; Whitmore, C, 1997
)
0.56
" The safety assessment was conducted through reports regarding adverse reactions and local tolerance in all visits and an overall tolerance at the end of the study."( Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks.
de C Almeida, F; de Faria, FA; do Nascimento, LV; Guedes, AC; Guerra, RM; Magalhães, GM, 2003
)
0.53
" Treatment-related adverse events were mostly mild-to-moderate and similar between active groups."( The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle.
Clark, SD; Graeber, M; Jones, TM; Liu, Y; Pariser, DM; Thiboutot, DM, 2005
)
0.63
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Therefore, the present study suggests that combined treatment with serial glycolic acid peels, azelaic acid cream and adapalene gel should be considered as an effective and safe therapy in recalcitrant melasma."( Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma.
Arca, E; Erbil, H; Kurumlu, Z; Sezer, E; Taştan, B, 2007
)
0.55
" Evaluations included lesion count reduction, subject's assessment of acne, adverse events, and cutaneous tolerability."( Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris.
Gold, MH; Graeber, M; Liu, Y; Morris, A; Pariser, DM; Westmoreland, P, 2007
)
0.57
" Discontinuations due to adverse events were low (2."( Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris.
Gold, MH; Graeber, M; Liu, Y; Morris, A; Pariser, DM; Westmoreland, P, 2007
)
0.57
"These findings are consistent with previous clinical findings and support the use of a once-daily adapalene/BP fixed-dose combination as a safe and effective treatment in the long-term management of acne."( Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris.
Gold, MH; Graeber, M; Liu, Y; Morris, A; Pariser, DM; Westmoreland, P, 2007
)
0.79
" Safety was monitored through adverse events and laboratory tests."( Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study.
Harada, S; Kawashima, M; Loesche, C; Miyachi, Y, 2008
)
1.79
" Adapalene was well tolerated, with adverse events that were mostly mild-to-moderate and transient in nature."( Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study.
Harada, S; Kawashima, M; Loesche, C; Miyachi, Y, 2008
)
2.7
" Adapalene was safe and well tolerated, consistent with the good tolerability profile demonstrated in other patient populations."( Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study.
Harada, S; Kawashima, M; Loesche, C; Miyachi, Y, 2008
)
2.7
" Treatment-related, dermatologic adverse events were experienced by 21% of subjects and dry skin, skin discomfort, and scaling were reported by 10."( Long-term safety and efficacy study of adapalene 0.3% gel.
Graeber, M; Hwa, J; Liu, Y; Thiboutot, DM; Weiss, JS, 2008
)
0.62
" Local adverse effects, including erythema, dryness, itching, and stinging, occur frequently during the early treatment phase."( Topical retinoids in acne vulgaris: update on efficacy and safety.
Gollnick, H; Thielitz, A, 2008
)
0.35
" Treatment-related adverse events (AEs) occurred in 48."( Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris.
Alió, AB; Barnard, J; Fischer, TC; Wohlrab, J; Zouboulis, CC, 2009
)
0.35
" Safety and tolerability was assessed on the basis of physical examination and monitoring of treatment-emergent adverse events."( Efficacy, safety, and tolerability of microsphere adapalene vs. conventional adapalene for acne vulgaris.
Baliga, VP; Dhurat, R; Dongre, P; Ghosh, S; Rao, GR; Sharma, A, 2009
)
0.61
"5% (adapalene-BPO) is efficacious and safe in the treatment of acne patients aged 12 years or older, as demonstrated in three randomized and controlled studies."( Treatment of 2,453 acne vulgaris patients aged 12-17 years with the fixed-dose adapalene-benzoyl peroxide combination topical gel: efficacy and safety.
Dirschka, T; Eichenfield, LE; Graeber, M; Jorizzo, JL; Kerrouche, N; Lynde, C; Taub, AF, 2010
)
1.15
" We report the fourth published case of acne vulgaris treated with isotretinoin in an individual with CGD, with a safe and successful outcome."( Safe and successful treatment of acne vulgaris with isotretinoin in a patient with chronic granulomatous disease.
Alonso-de-Celada, RM; de-Lucas Laguna, R,
)
0.13
" Significantly lower incidence and lesser intensity of adverse events like local irritation (4."( Efficacy and safety of a nano-emulsion gel formulation of adapalene 0.1% and clindamycin 1% combination in acne vulgaris: a randomized, open label, active-controlled, multicentric, phase IV clinical trial.
Bajaj, B; Kelkar, A; Kubavat, A; Mittal, R; Modi, A; Mukhopadhyay, A; Prasad, S; Sheikh, S; Swarnkar, B; Vedamurthy, M,
)
0.38
" Most of adverse events to adapalene and many on tretinoin group were related to skin irritation, dry skin, scaling, pruritus, burning, and postinflammatory hyperpigmentation."( Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV).
Bonifaz, A; Espíndola, YS; Ponce-Olivera, RM; Tirado-Sánchez, A, 2013
)
1
" Safety was assessed through evaluations of adverse events (AEs) and local tolerability [erythema, scaling, dryness, and stinging/burning on scales ranging from 0 (none) to 3 (severe)]."( Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides.
Draelos, Z; Eichenfield, LF; Hebert, AA; Liu, H; Lucky, AW; Manna, V; Rudisill, D; Stein Gold, L; Sugarman, J, 2013
)
0.61
" The changes of acne lesion count (efficacy), any adverse effect (safety), and the patients' overall satisfaction (tolerability) were compared after 3 months of follow-up."( The efficacy, safety, and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris: a randomized trial.
Babaeinejad, SH; Fouladi, RF, 2013
)
0.65
" The changes of acne lesion count (efficacy), any adverse effect (safety), and the patients' overall satisfaction (tolerability) were compared after 3 months of follow-up."( The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial.
Babaeinejad, SH; Fouladi, RF, 2013
)
0.66
" Based on the results from this analysis, adapalene-BPO is a safe and effective treatment for acne in black skin."( A subgroup analysis to evaluate the efficacy and safety of adapalene-benzoyl peroxide topical gel in black subjects with moderate acne.
Alexis, AF; Callender, VD; Johnson, LA; Kerrouche, N, 2014
)
0.91
"Growing numbers of post-adolescent females are suffering from treatment-resistant or relapsing adult acne forms, therefore requiring the definition of safe and effective treatment options for this burdening disease."( A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne.
Gollnick, H; Kropf, S; Lux, A; Papakonstantinou, E; Thielitz, A; Wiede, A, 2015
)
0.63
" No serious adverse events were reported."( Safety and efficacy of adapalene 0.1% / benzoyl peroxide 2.5% in the long-term treatment of predominantly moderate acne with or without concomitant medication - results from the non-interventional cohort study ELANG.
Friedrich, M; Gollnick, HP; Jäckel, A; Jöstingmeyer, P; Peschen, M; Pettker, R; Pier, A; Porombka, D; Rojo Pulido, I; Streit, V, 2015
)
0.73
"In consistence with previous clinical findings, the use of adapalene-BPO in daily practice routine is safe and effective in the long-term management of patients with moderate to severe acne."( Safety and efficacy of adapalene 0.1% / benzoyl peroxide 2.5% in the long-term treatment of predominantly moderate acne with or without concomitant medication - results from the non-interventional cohort study ELANG.
Friedrich, M; Gollnick, HP; Jäckel, A; Jöstingmeyer, P; Peschen, M; Pettker, R; Pier, A; Porombka, D; Rojo Pulido, I; Streit, V, 2015
)
0.97
" Safety assessments included adverse events (AEs) and tolerability."( Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Oral Doxycycline in Subjects With Severe Inflammatory Acne Who Are Candidates for Oral Isotretinoin.
Baldwin, H; Del Rosso, JQ; Johnson, SM; Lain, EL; Landis, M; Rendon, M; Rueda, MJ; Stein Gold, L; Tanghetti, E; Weiss, J, 2018
)
0.79
"3% A/BPO + DOX is an effective and safe treatment option for severe inflammatory AV, before starting OI treatment, or as an alternative when OI cannot be used."( Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Oral Doxycycline in Subjects With Severe Inflammatory Acne Who Are Candidates for Oral Isotretinoin.
Baldwin, H; Del Rosso, JQ; Johnson, SM; Lain, EL; Landis, M; Rendon, M; Rueda, MJ; Stein Gold, L; Tanghetti, E; Weiss, J, 2018
)
0.79
" No drug was detected in blood/liver which in addition to an absence of any adverse effect on liver and enzymes showed the potential of adapalene loaded nano-emulsion gel as a novel carrier for topical delivery of adapalene."( Delivery of adapalene using a novel topical gel based on tea tree oil nano-emulsion: Permeation, antibacterial and safety assessments.
Amani, A; Ghaemi, B; Najafi-Taher, R, 2018
)
1.06
" Treatment-emergent adverse events and cutaneous safety/tolerability were also assessed."( Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Baldwin, H; Beer, K; Bhatt, V; Callender, V; Draelos, Z; Gold, M; Kircik, LH; Lain, E; Pariser, DM; Pillai, R; Sadick, N; Stein Gold, L; Tanghetti, EA; Weiss, JS, 2022
)
0.94
" IDP-126 was well tolerated, with most treatment-emergent adverse events of mild-to-moderate severity."( Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Baldwin, H; Beer, K; Bhatt, V; Callender, V; Draelos, Z; Gold, M; Kircik, LH; Lain, E; Pariser, DM; Pillai, R; Sadick, N; Stein Gold, L; Tanghetti, EA; Weiss, JS, 2022
)
0.94
" The no observable adverse event level (NOAEL) for adapalene teratogenicity was established in rat and rabbit embryo-fetal development studies."( Safe Use of Adapalene 0.1 % Gel in a non-Prescription Environment.
Griffin, S; Mallavalli, S; Meckfessel, M; Wagner, N; Weiss, J, 2021
)
1.25
"1% Gel is a safe and effective medication for the treatment of acne in a non-prescription environment."( Safe Use of Adapalene 0.1 % Gel in a non-Prescription Environment.
Griffin, S; Mallavalli, S; Meckfessel, M; Wagner, N; Weiss, J, 2021
)
1

Pharmacokinetics

ExcerptReferenceRelevance
" A subfraction ("CD271GB") consisting essentially of 2'- and 3'-CD271G was used for pharmacokinetic studies."( Synthesis, high-performance liquid chromatography-nuclear magnetic resonance characterization and pharmacokinetics in mice of CD271 glucuronide.
Albert, K; Lacker, TS; Nau, H; Rühl, R; Strohschein, S; Thiel, R, 2001
)
0.31
"To develop a simple pharmacodynamic (PD) assay for the evaluation of the bioequivalence of topically applied retinoid products."( Assessing the bioequivalence of topical retinoid products by pharmacodynamic assay.
Franz, TJ; Lehman, PA, 2012
)
0.38

Compound-Compound Interactions

The tested skincare combined with adapalene and benzoyl peroxide combination provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne.

ExcerptReferenceRelevance
" Five days a week, the three materials (benzoyl peroxide, clindamycin phosphate, and erythromycin) were applied in a nonocclusive manner either alone or in combination with adapalene gel on seven cutaneous sites on the upper back."( Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments.
Caron, D; Clucas, A; Sorba, V; Verschoore, M, 1997
)
0.82
"1% when applied in combination with clindamycin phosphate lotion 1%, erythromycin gel 2%, benzoyl peroxide gel 5%, or erythromycin-benzoyl peroxide gel."( Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents.
Baker, MD; Brand, B; Georgeian, K; Gilbert, R; Greenspan, A; Poncet, M; Soloff, AM, 2003
)
0.6
" Adapalene alone or in combination with clindamycin topical solution was well tolerated."( A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%.
Li, LF; Tu, YT; Zhang, JZ; Zheng, J, 2004
)
1.48
"By week 12, dapsone gel combined with any of the three additional treatments reduced the mean number of inflammatory lesions."( Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study.
Abramovits, W; Eichenfield, LF; Fleischer, AB; Garrett, S; Lucky, A; Shalita, A, 2010
)
0.64
"Dapsone gel in combination with adapalene gel or benzoyl peroxide gel is safe and well tolerated for the treatment of acne vulgaris."( Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study.
Abramovits, W; Eichenfield, LF; Fleischer, AB; Garrett, S; Lucky, A; Shalita, A, 2010
)
0.92
"In conclusion, the tested skincare combined with a fixed adapalene and benzoyl peroxide combination provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne."( A skincare combined with combination of adapalene and benzoyl peroxide provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne.
Bouloc, A; Chadoutaud, B; Dréno, B; Imko-Walczuk, B; Moga, A; Roo, E, 2017
)
0.97

Bioavailability

ExcerptReferenceRelevance
" Significantly enhanced dermal bioavailability (AD-2."( Codelivery of benzoyl peroxide & adapalene using modified liposomal gel for improved acne therapy.
Jain, S; Kale, DP; Katiyar, SS; Swami, R, 2018
)
0.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Nano-based carriers have been developed to improve solubility and bioavailability of adapalene and other acne treatment drugs."( A topical gel of tea tree oil nanoemulsion containing adapalene versus adapalene marketed gel in patients with acne vulgaris: a randomized clinical trial.
Amani, A; Ehsani, A; Eslami Farsani, V; Jafarzadeh Kohneloo, A; Mehdizade Rayeni, N; Moghimi, HR; Najafi-Taher, R, 2022
)
1.19

Dosage Studied

ExcerptRelevanceReference
" In this study, we compared, in dose-response experiments, the biologic activities of retinoic acid and CD271, a substance unable to bind to CRABP, but able to bind to nuclear retinoic acid receptors (RAR)."( Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP).
Asselineau, D; Cavey, MT; Darmon, M; Shroot, B, 1992
)
0.28
" The influence of the following parameters on CD 271 release from the formulations was investigated: receptor fluid composition, occlusion, weight of tested formulation, and dosage form type."( Influence of formulation, receptor fluid, and occlusion, on in vitro drug release from topical dosage forms, using an automated flow-through diffusion cell.
Demichelis, G; Jamoulle, JC; Rolland, A; Shroot, B, 1992
)
0.28
"025% gel, both topical treatments for acne, in a once-daily dosage regimen for 12 weeks."( Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris.
Baker, M; Berger, RS; Chalker, DM; Ellis, CN; Katz, IH; Loesche, C; Millikan, LE; Mills, OH; Smith, EB; Swinyer, LJ; Verschoore, M, 1998
)
0.66
"By several measures, adapalene cream and gel were less irritating upon multiple dosing than various tretinoin creams and gels."( Comparative irritancy study among retinoid creams and gels.
Bowman, JP; Lockhart, L; Novack, GD; Potrebka, J; Toole, JW, 1999
)
0.62
" After a single subcutaneous injection at a dosage of 30 mg/kg the substance showed considerable uptake and metabolism to CD271 indicating that CD271GB could serve as a prodrug for CD271."( Synthesis, high-performance liquid chromatography-nuclear magnetic resonance characterization and pharmacokinetics in mice of CD271 glucuronide.
Albert, K; Lacker, TS; Nau, H; Rühl, R; Strohschein, S; Thiel, R, 2001
)
0.31
" The SLN were prepared using pre-emulsion sonication method and incorporated into convenient topical dosage form, hydrogels."( Formulation and evaluation of Adapalene-loaded nanoparticulates for epidermal localization.
Bhalekar, M; Madgulkar, A; Upadhaya, P, 2015
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
dermatologic drugA drug used to treat or prevent skin disorders or for the routine care of skin.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
EC 2.7.11.22 (cyclin-dependent kinase) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of cyclin-dependent kinase (EC 2.7.11.22).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
adamantanesCompounds containing an adamantane skeleton.
naphthoic acidAn aromatic carboxylic acid that consists of a naphthalene skeleton substituted by one or more carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency27.00500.004023.8416100.0000AID485290; AID489007
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency23.91453.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency5.37810.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency79.43280.031637.5844354.8130AID504865
AR proteinHomo sapiens (human)Potency27.12360.000221.22318,912.5098AID1259243; AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.95520.001022.650876.6163AID1224838; AID1224893
EWS/FLI fusion proteinHomo sapiens (human)Potency3.24520.001310.157742.8575AID1259252; AID1259253; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.68220.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency2.24800.003041.611522,387.1992AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.18400.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency19.64270.375827.485161.6524AID743217; AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.52440.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency9.43840.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.60110.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.01330.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency6.00700.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency21.313819.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency11.98450.039147.5451146.8240AID1224845; AID1224896
Bloom syndrome protein isoform 1Homo sapiens (human)Potency28.18380.540617.639296.1227AID2528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency1.41470.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency26.77760.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency20.42570.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency1.18860.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency7.11450.005612.367736.1254AID624032; AID624044
lamin isoform A-delta10Homo sapiens (human)Potency3.16230.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.01190.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency2.37100.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.01190.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency1.77830.009610.525035.4813AID1479145
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency15.84890.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Retinoic acid receptor alphaHomo sapiens (human)Ki1.10000.00100.94856.5000AID200139
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)2.30000.17004.559010.0000AID1594139
Retinoic acid receptor betaHomo sapiens (human)Ki0.03400.00071.56739.9010AID198222
Retinoic acid receptor gamma Homo sapiens (human)Ki0.13000.00001.997510.0000AID198738
Aspartate aminotransferase, cytoplasmicHomo sapiens (human)IC50 (µMol)21.79005.39005.39005.3900AID1850930
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)2.30000.17004.559010.0000AID1594139
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)100.00000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)3.60000.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)3.60000.03903.55529.8000AID1594140; AID1594141
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor alphaHomo sapiens (human)EC50 (µMol)0.02200.00020.17902.5119AID1380632
Retinoic acid receptor betaHomo sapiens (human)EC50 (µMol)0.00200.00030.23116.9000AID1380634
Retinoic acid receptor gamma Homo sapiens (human)EC50 (µMol)0.00310.00020.06130.6480AID1380631
Glycine receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)1.30000.32001.45774.2000AID1203550
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (305)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
ureteric bud developmentRetinoic acid receptor alphaHomo sapiens (human)
neural tube closureRetinoic acid receptor alphaHomo sapiens (human)
liver developmentRetinoic acid receptor alphaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor alphaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
protein phosphorylationRetinoic acid receptor alphaHomo sapiens (human)
germ cell developmentRetinoic acid receptor alphaHomo sapiens (human)
female pregnancyRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of translationRetinoic acid receptor alphaHomo sapiens (human)
hippocampus developmentRetinoic acid receptor alphaHomo sapiens (human)
prostate gland developmentRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of granulocyte differentiationRetinoic acid receptor alphaHomo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor alphaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor alphaHomo sapiens (human)
response to estradiolRetinoic acid receptor alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of type II interferon productionRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of tumor necrosis factor productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-13 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-4 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-5 productionRetinoic acid receptor alphaHomo sapiens (human)
response to vitamin ARetinoic acid receptor alphaHomo sapiens (human)
response to cytokineRetinoic acid receptor alphaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of apoptotic processRetinoic acid receptor alphaHomo sapiens (human)
apoptotic cell clearanceRetinoic acid receptor alphaHomo sapiens (human)
response to ethanolRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of neuron differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell cycleRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of synaptic plasticityRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of bindingRetinoic acid receptor alphaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
Sertoli cell fate commitmentRetinoic acid receptor alphaHomo sapiens (human)
limb developmentRetinoic acid receptor alphaHomo sapiens (human)
face developmentRetinoic acid receptor alphaHomo sapiens (human)
trachea cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
chondroblast differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
cellular response to lipopolysaccharideRetinoic acid receptor alphaHomo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
cellular response to estrogen stimulusRetinoic acid receptor alphaHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionRetinoic acid receptor alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ureteric bud developmentRetinoic acid receptor betaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor betaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor betaHomo sapiens (human)
apoptotic processRetinoic acid receptor betaHomo sapiens (human)
signal transductionRetinoic acid receptor betaHomo sapiens (human)
striatum developmentRetinoic acid receptor betaHomo sapiens (human)
neurogenesisRetinoic acid receptor betaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor betaHomo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor betaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor betaHomo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor betaHomo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor betaHomo sapiens (human)
embryonic digestive tract developmentRetinoic acid receptor betaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor betaHomo sapiens (human)
neural precursor cell proliferationRetinoic acid receptor betaHomo sapiens (human)
stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
cell differentiationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
neural tube closureRetinoic acid receptor gamma Homo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor gamma Homo sapiens (human)
growth plate cartilage chondrocyte growthRetinoic acid receptor gamma Homo sapiens (human)
apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
regulation of cell sizeRetinoic acid receptor gamma Homo sapiens (human)
anterior/posterior pattern specificationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of gene expressionRetinoic acid receptor gamma Homo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor gamma Homo sapiens (human)
regulation of myelinationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor gamma Homo sapiens (human)
response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
multicellular organism growthRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of programmed cell deathRetinoic acid receptor gamma Homo sapiens (human)
regulation of myeloid cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
canonical Wnt signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
face developmentRetinoic acid receptor gamma Homo sapiens (human)
trachea cartilage developmentRetinoic acid receptor gamma Homo sapiens (human)
prostate gland epithelium morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
Harderian gland developmentRetinoic acid receptor gamma Homo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cellular response to leukemia inhibitory factorRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
gluconeogenesisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
2-oxoglutarate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
oxaloacetate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glycerol biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate catabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
Notch signaling pathwayAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to aspartateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to 2-oxoglutarateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cellular response to insulin stimulusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
response to glucocorticoidAspartate aminotransferase, cytoplasmicHomo sapiens (human)
fatty acid homeostasisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlycine receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transportGlycine receptor subunit alpha-1Homo sapiens (human)
muscle contractionGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-1Homo sapiens (human)
acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
visual perceptionGlycine receptor subunit alpha-1Homo sapiens (human)
adult walking behaviorGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal action potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuromuscular process controlling postureGlycine receptor subunit alpha-1Homo sapiens (human)
negative regulation of transmission of nerve impulseGlycine receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, glycinergicGlycine receptor subunit alpha-1Homo sapiens (human)
righting reflexGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-1Homo sapiens (human)
response to alcoholGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-1Homo sapiens (human)
positive regulation of acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (105)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
mRNA regulatory element binding translation repressor activityRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activityRetinoic acid receptor alphaHomo sapiens (human)
transcription coactivator bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor alphaHomo sapiens (human)
signaling receptor bindingRetinoic acid receptor alphaHomo sapiens (human)
protein bindingRetinoic acid receptor alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor alphaHomo sapiens (human)
protein domain specific bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
histone deacetylase bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase B bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor alphaHomo sapiens (human)
mRNA 5'-UTR bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase A bindingRetinoic acid receptor alphaHomo sapiens (human)
alpha-actinin bindingRetinoic acid receptor alphaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor betaHomo sapiens (human)
DNA bindingRetinoic acid receptor betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor betaHomo sapiens (human)
protein-containing complex bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor betaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor gamma Homo sapiens (human)
DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
chromatin bindingRetinoic acid receptor gamma Homo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor gamma Homo sapiens (human)
protein bindingRetinoic acid receptor gamma Homo sapiens (human)
zinc ion bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor gamma Homo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear receptor activityRetinoic acid receptor gamma Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
L-aspartate:2-oxoglutarate aminotransferase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
phosphatidylserine decarboxylase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
pyridoxal phosphate bindingAspartate aminotransferase, cytoplasmicHomo sapiens (human)
L-cysteine transaminase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
transmembrane signaling receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingGlycine receptor subunit alpha-1Homo sapiens (human)
zinc ion bindingGlycine receptor subunit alpha-1Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
taurine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (62)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
nucleusRetinoic acid receptor alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
nucleolusRetinoic acid receptor alphaHomo sapiens (human)
cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
cytosolRetinoic acid receptor alphaHomo sapiens (human)
plasma membraneRetinoic acid receptor alphaHomo sapiens (human)
actin cytoskeletonRetinoic acid receptor alphaHomo sapiens (human)
dendriteRetinoic acid receptor alphaHomo sapiens (human)
perinuclear region of cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
chromatinRetinoic acid receptor alphaHomo sapiens (human)
protein-containing complexRetinoic acid receptor alphaHomo sapiens (human)
nucleusRetinoic acid receptor alphaHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor betaHomo sapiens (human)
cytoplasmRetinoic acid receptor betaHomo sapiens (human)
chromatinRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleoplasmRetinoic acid receptor gamma Homo sapiens (human)
cytoplasmRetinoic acid receptor gamma Homo sapiens (human)
membraneRetinoic acid receptor gamma Homo sapiens (human)
chromatinRetinoic acid receptor gamma Homo sapiens (human)
transcription regulator complexRetinoic acid receptor gamma Homo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytoplasmAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
extracellular exosomeAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
external side of plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
membraneGlycine receptor subunit alpha-1Homo sapiens (human)
dendriteGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal cell bodyGlycine receptor subunit alpha-1Homo sapiens (human)
perikaryonGlycine receptor subunit alpha-1Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory synapseGlycine receptor subunit alpha-1Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (122)

Assay IDTitleYearJournalArticle
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID365036Induction of apoptosis in human MDA-MB-231 cells at 2.0 uM after 96 hrs by acridine orange staining2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID365033Induction of apoptosis in human HL60R cells at 0.1 uM after 24 hrs by acridine orange staining2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID1594142Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduct2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID365040Growth inhibition of HMVE cells at 0.5 uM after 72 hrs by alamar blue method2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID198738Binding affinity to retinoic acid receptor (RAR) gamma using [3H]CD 367 as radioligand1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1203550Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents after 1 to 4 days by two-electrode voltage clamp assay2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID1380638Unbound fraction in plasma (unknown origin)2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID365034Induction of apoptosis in human HL60R cells at 1.0 uM after 24 hrs by acridine orange staining2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1203551Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594143Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reducti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID365039Growth inhibition of HMVE cells after 72 hrs by alamar blue method2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID198222Binding affinity to retinoic acid receptor beta using [3H]CD 367 as radioligand1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1594136Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1380635Selectivity index, ratio of EC50 for GAL4 DNA-binding domain-tagged RARbeta (unknown origin) ligand-binding domain expressed in human HG5LN cells to EC50 for GAL4 DNA-binding domain-tagged RARgamma (unknown origin) ligand-binding domain expressed in human2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID68777In vitro promotion of plasminogen activator secretion from F9 (murine teratocarcinoma) cells.1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID200139Binding affinity to retinoic acid receptor alpha using [3H]CD 367 as radioligand1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1203549Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 1 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID1380632Agonist activity at GAL4 DNA-binding domain-tagged RARalpha (unknown origin) ligand-binding domain expressed in human HG5LN cells incubated for 18 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
AID1850930Inhibition of C-terminal His6-tagged human recombinant GOT1 expressed in Escherichia coli BL21 (DE3) cells using aspartic acid and alpha-ketoglutaric acid as substrates incubated in presence of MDH1 and NADH2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID1380633Selectivity index, ratio of EC50 for GAL4 DNA-binding domain-tagged RARalpha (unknown origin) ligand-binding domain expressed in human HG5LN cells to EC50 for GAL4 DNA-binding domain-tagged RARgamma (unknown origin) ligand-binding domain expressed in huma2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID365035Induction of apoptosis in human MDA-MB-231 cells at 1.0 uM after 96 hrs by acridine orange staining2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1203552Modulation of human alpha7 nAChR expressed in Xenopus laevis oocytes assessed as effect on acetylcholine-induced currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID1380631Agonist activity at GAL4 DNA-binding domain-tagged RARgamma (unknown origin) ligand-binding domain expressed in human HG5LN cells incubated for 18 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
AID1380634Agonist activity at GAL4 DNA-binding domain-tagged RARbeta (unknown origin) ligand-binding domain expressed in human HG5LN cells incubated for 18 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594138Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction i2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346788Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID1346740Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID1346786Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (404)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's47 (11.63)18.2507
2000's122 (30.20)29.6817
2010's168 (41.58)24.3611
2020's67 (16.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.98 (24.57)
Research Supply Index6.40 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index226.36 (26.88)
Search Engine Supply Index3.83 (0.95)

This Compound (67.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials150 (33.48%)5.53%
Reviews67 (14.96%)6.00%
Case Studies40 (8.93%)4.05%
Observational3 (0.67%)0.25%
Other188 (41.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (86)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Comparative Efficacy of an Over the Counter Light Therapy Mask vs Over the Counter Topical Benzoyl Peroxide 2.5% and Used in Combination With Over the Counter Adapalene Gel 0.1% for Mild to Moderate Acne [NCT03650881]0 participants (Actual)Interventional2018-08-07Withdrawn(stopped due to no eligible subjects were enrolled)
Efficacy of Epiduo and Adherence of Patients Between 12 to 20 Years Using This Drug First Time in the Monotherapy of Moderate Inflammatory Acne [NCT01220102]3,113 participants (Actual)Observational2010-05-31Completed
A Randomized, Double Blind, Placebo-Controlled Clinical Trial of the Effects of Oral Zinc Gluconate Among Diagnosed Acne Vulgaris Patients [NCT05096312]Phase 423 participants (Actual)Interventional2018-12-21Completed
Evaluation of Efficacy and Safety of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris [NCT01149330]Phase 475 participants (Actual)Interventional2010-07-31Completed
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products (Retin-A Micro Gel, 0.04% Pump and Epiduo Gel) Using a Split-Face Model [NCT00952523]Phase 4162 participants (Actual)Interventional2009-07-31Completed
A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of Adapalene Gel 0.1% (PLIVA Research & Development Ltd.) Compared to Differin® (Adapalene 0.1%) Topical Gel (Galderma Laboratori [NCT01182636]Phase 1601 participants (Actual)Interventional2007-07-31Completed
Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia: A Multicenter Clinical Trial [NCT03626298]Phase 4125 participants (Actual)Interventional2016-08-01Completed
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects [NCT02932267]Phase 350 participants (Actual)Interventional2017-02-02Completed
A Multi-center, Randomized, Single-blind, Paralelle, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Moderate Acne Vulgaris [NCT03615768]Phase 31,617 participants (Actual)Interventional2018-08-14Completed
Plantar Wart Treatment Using Adapalene Gel [NCT04823845]Early Phase 10 participants (Actual)Interventional2022-05-01Withdrawn(stopped due to Study never received IRB approval.)
A Multi-center, Double-blind, Randomized, Placebo, Controlled, Parallel-group Study, Comparing Adapalene/BP Gel, 0.3%/2.5% to EPIDUO® FORTE GEL and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris [NCT02709902]Phase 1460 participants (Actual)Interventional2015-09-30Completed
Molecular and Clinical Study of the Effect of Zaxcell Versus Effezel in the Inflammatory and Scarring Process of Moderate and Severe Acne [NCT03076320]Phase 1/Phase 282 participants (Actual)Interventional2017-03-27Completed
The Use of Oracea and Epiduo Forte in Severe Acne Patients [NCT03457636]Phase 422 participants (Actual)Interventional2018-03-19Completed
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene Gel 0.3% to Differin® (Adapalene Gel 0.3%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris [NCT02411942]Phase 1753 participants (Actual)Interventional2014-08-31Completed
Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne [NCT02338544]1,388 participants (Actual)Observational2015-01-31Completed
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris [NCT03650361]Phase 3755 participants (Actual)Interventional2018-09-17Completed
Randomized Controlled Trial Comparing the Efficacy of Adapalene 0.1% Gel to 10% Benzoyl Peroxide in Treating Molluscum Contagiosum. [NCT05536882]Phase 3150 participants (Anticipated)Interventional2023-02-28Not yet recruiting
A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris [NCT00599521]Phase 31,067 participants (Actual)Interventional2007-11-30Completed
Vitamin D Supplementation in Combination With Azithromycin and Topical Retinoid for Acne: A Randomized Controlled Trial [NCT06141330]58 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Vitamin D and Its Topical Analogues: A Possible Role in the Pathogenesis and Treatment of Acne Vulgaris [NCT03866447]Phase 480 participants (Anticipated)Interventional2019-10-01Not yet recruiting
Efficacy and Safety Comparison of Epiduo Gel Associated With Lymecycline 300 mg Capsules Versus Epiduo Vehicle Gel Associated With Lymecycline 300 mg Capsules in the Treatment of Moderate to Severe Acne Vulgaris [NCT01014689]Phase 3378 participants (Actual)Interventional2009-08-31Completed
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris [NCT00671749]Phase 4100 participants (Actual)Interventional2007-12-31Completed
A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris [NCT00887484]Phase 450 participants (Actual)Interventional2009-02-28Completed
A Single-blind, Randomized, Comparative Split-face Study Evaluating the Tolerability of Clindamycin and Benzoyl Peroxide Gel to Benzoyl Peroxide/Adapalene Gel in the Treatment of Acne Vulgaris. [NCT00964223]Phase 428 participants (Actual)Interventional2009-07-31Completed
A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study F [NCT04104685]Phase 2446 participants (Actual)Interventional2019-09-18Completed
A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream With Resveratrol , Replenix Power of Three Cream With Resveratrol With Adapalene and Benzoyl Peroxid [NCT03563365]Phase 443 participants (Actual)Interventional2018-06-04Terminated(stopped due to Lack of Funding)
The Lipid Profile of the Skin Surface in Acne [NCT02180425]30 participants (Actual)Observational2013-11-30Completed
Single-blind, Multicenter, Parallel, Comparative, Randomized, Phase 4 Clinical Trial for the Evaluation of the Quality of Life, Efficacy and Tolerance of Duac® Gel Against Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris. [NCT00807014]Phase 4169 participants (Actual)Interventional2006-11-30Completed
A Placebo Control, Multicenter, Randomized, Double Blind, Multi-formula Groups, and Parallel Phase Ⅰb+Ⅱa Study Evaluating the Safety and Efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne [NCT02593383]Phase 1/Phase 2245 participants (Actual)Interventional2015-03-01Completed
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using a Split-Face Model [NCT00714714]Phase 425 participants (Actual)Interventional2008-01-31Completed
Placebo-Controlled, Investigator Blinded, Explorative Trial to Evaluate the Anti-inflammatory Effect of Multiple Topical Applications of R115866 Gel (0.35%) in Two Models of Cutaneous Inflammation in Healthy Male Subjects [NCT00719121]Phase 112 participants (Actual)Interventional2006-11-30Completed
A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjec [NCT00421993]Phase 31,670 participants (Actual)Interventional2006-10-31Completed
National Clinical Trial, Phase III, Monocentric, Randomized, Open, Controlled, Parallel Study to Assess the Non-inferiority of Dalap Duo® Product (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel Cream) Compared to Epiduo® (0,1% Adapalene and 2,5% Benzoyl Per [NCT02716090]Phase 30 participants (Actual)InterventionalWithdrawn(stopped due to Due to budget limitations, the company decided to withdraw this study.)
Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Topical Antibiotic and Benzoyl Peroxide to Benzoyl Peroxide and Adapalene Topical Gel Acne Medications [NCT00926367]Phase 452 participants (Actual)Interventional2009-05-31Completed
Phase IV An Evaluator-Blind Controlled Parallel-Group Study To Assess Efficacy And Safety Of Skinoren® 15% Gel And Differin® 0,1% Gel For The Treatment And Maintenance Treatment Of Facial Acne Vulgaris And Late-Type Acne In Females [NCT01387048]Phase 460 participants (Actual)Interventional2011-08-31Completed
Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura [NCT01485367]Phase 220 participants (Anticipated)Interventional2011-12-31Recruiting
Single-blinded, Multicenter, Randomized, Comparative Study of Efficacy and Safety of Adapalene Gel 0.3% Versus Tretinoin Emollient Cream 0.05% in the Treatment of Cutaneous Photoaging. [NCT01406080]Phase 3128 participants (Actual)Interventional2013-01-31Completed
Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With Doxycycline Hyclate 100 mg Tablets Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel Associated With Doxycycline Hyclate 100 mg Tablets in the Treatment o [NCT00688064]Phase 3459 participants (Actual)Interventional2008-08-31Completed
A Multi-Center Clinical Trial to Evaluate the Efficacy of Two Acne Treatments [NCT02755545]Phase 4127 participants (Actual)Interventional2016-05-01Completed
A Comparative Study of Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream, for the Treatment of Photodamage [NCT00647556]Phase 330 participants (Actual)Interventional2008-04-30Completed
Epiduo in the Long-term Treatment of Moderate to Severe Acne With or Without Concomitant Medication [NCT01618773]6,036 participants (Actual)Observational2012-06-30Completed
A Phase 3, Randomized, Double-blind, Multi-dose Study to Evaluate the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG 5%) When Co-administered With Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% in the Treatment of Acne Vulgaris. [NCT00151541]Phase 3301 participants (Actual)Interventional2005-02-28Completed
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model [NCT00919191]Phase 426 participants (Actual)Interventional2009-04-30Completed
Multi-Centre, Single-Blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Duac® Gel And Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris [NCT00160394]Phase 4130 participants (Actual)Interventional2004-12-31Completed
A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study Comparing 0.3% Adapalene Topical Gel (Actavis Mid Atlantic LLC) to Differin® (0.3 % Adapalene Topical Gel) (Galderma Laboratories, L.P.) and Both Active Treatments to a Vehi [NCT01095640]1,159 participants (Actual)Interventional2009-03-31Completed
Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial [NCT02721173]Phase 460 participants (Actual)Interventional2016-04-30Completed
A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris [NCT00598832]Phase 31,075 participants (Actual)Interventional2007-11-30Completed
A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L [NCT01501799]885 participants (Actual)Interventional2011-07-31Completed
Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects [NCT02899000]Phase 4186 participants (Actual)Interventional2016-07-29Completed
[NCT01425320]Phase 10 participants (Actual)Interventional2013-01-31Withdrawn(stopped due to Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.)
"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients." [NCT05855629]59 participants (Actual)Interventional2022-02-18Active, not recruiting
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris [NCT01209949]Phase 430 participants (Actual)Interventional2010-10-31Completed
Efficacy and Safety Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris [NCT00883233]Phase 3123 participants (Actual)Interventional2009-04-30Completed
Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin [NCT01046565]Phase 175 participants (Actual)Interventional2010-01-31Completed
Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA as Adjuvant Therapy for Acne Vulgaris Mild to Moderate [NCT05497323]Phase 1284 participants (Actual)Interventional2022-08-01Active, not recruiting
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 0.1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris [NCT00441415]Phase 3272 participants (Actual)Interventional2007-02-28Completed
Efficacy Comparison Study of Topical Aminolaevulinic Acid-Photodynamic Therapy Versus Adapalene Gel 0.1% Plus Doxycycline for Treatment of Moderate Acne Vulgaris. Randomized, Simple Blind, Controlled Trial. [NCT01245946]Phase 246 participants (Actual)Interventional2010-10-31Completed
A Long-term Safety and Efficacy Study of a Fixed Combination of Adapalene 0.1% and Benzoyl Peroxide 2.5% (Adapalene and Benzoyl Peroxide Topical Gel) Gel in Subjects With Acne Vulgaris [NCT00446043]Phase 3452 participants (Actual)Interventional2004-02-17Completed
A Double-blind, Randomized, Placebo Controlled Study to Compare Adapalene Gel 0.1% to Differin Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris [NCT04797793]Early Phase 1978 participants (Actual)Interventional2020-05-18Completed
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris [NCT02249104]Phase 428 participants (Actual)Interventional2014-08-31Completed
A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris [NCT01138735]Phase 4285 participants (Actual)Interventional2010-06-30Completed
An Evaluator-blind, Randomized, Vehicle-controlled Efficiency of Adjunctive Usage of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel for Improvement of Local Tolerance in Thai Acne Subjects [NCT02173054]Phase 3120 participants (Actual)Interventional2014-07-31Completed
Effect of Adding a Diet With Low Glycemic Index and Load During 12 Weeks for the Treatment of Moderate Acne in Adults: a Randomized Clinical Trial [NCT03585140]52 participants (Actual)Interventional2016-01-01Completed
A Pharmacokinetic Study to Compare the Systemic Exposure to Adapalene During Dermal Application of Either Differin® Gel, 0.3% (Adapalene 0.3%) or Differin® Gel, 0.1% (Adapalene 0.1%) for 30 Days in Subjects With Acne Vulgaris [NCT00660985]Phase 451 participants (Actual)Interventional2008-05-31Completed
An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris [NCT00696449]Phase 461 participants (Actual)Interventional2006-06-30Completed
[NCT00829049]Phase 4165 participants (Actual)Interventional2007-10-31Terminated(stopped due to Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.)
A Long Term Study of GK530G in Subjects With Acne Vulgaris [NCT01910064]Phase 3436 participants (Actual)Interventional2013-05-31Completed
Potential Combination Topical Therapy of Acne Vulgaris: a Randomized Controlled Trial Comparing Efficacy of DAP/FLU Micro-emulsion vs. Standard Therapy of Adapalene. [NCT05899699]Phase 220 participants (Anticipated)Interventional2023-06-05Not yet recruiting
Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery [NCT03573115]16 participants (Actual)Interventional2018-01-04Completed
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) an [NCT01742637]Phase 12,008 participants (Actual)Interventional2012-10-31Completed
[NCT01231334]Phase 4286 participants (Actual)Interventional2010-08-31Completed
Effect of Sample Medication Use and Application Instructions on Adherence to and Efficacy of Treatment of Patients With Mild to Moderate Acne With Epiduo(R) Gel [NCT01504204]Phase 420 participants (Actual)Interventional2011-12-31Completed
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris [NCT01951417]Phase 481 participants (Actual)Interventional2013-10-31Completed
Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin [NCT01046396]Phase 169 participants (Actual)Interventional2010-01-31Completed
Exploratory Study to Evaluate the Efficacy and Safety of CD07223 1.5% Gel and 0.5% Gel in Subjects With Acne [NCT01106807]Phase 273 participants (Actual)Interventional2010-04-30Completed
Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study. [NCT01213199]Phase 220 participants (Actual)Interventional2011-03-31Completed
[NCT02525549]Phase 3903 participants (Actual)Interventional2011-12-31Completed
A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjec [NCT00422240]Phase 31,656 participants (Anticipated)Interventional2006-06-30Completed
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Adapalene/BP Gel to Galderma's Epiduo (Adapalene/BP) Gel, and Both Treatments to a Vehicle Control in the Treatment of Acne Vulgaris [NCT03393494]Phase 3825 participants (Actual)Interventional2017-12-13Completed
Randomized, Double Blind, Placebo Controlled, Parallel Group Design, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Topical Adapalene Gel, 0.1 % in Healthy Males and Nonpregnant Female Subjects With Acne Vulgaris [NCT04329403]Phase 30 participants (Actual)Interventional2020-07-31Withdrawn(stopped due to Market reasons)
Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Vehicle Gel as a 6-month Acne Maintenance Treatment [NCT00687908]Phase 3243 participants (Actual)Interventional2008-11-30Completed
A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-week Treatment Switched to Tazorac® Cream, 0.1% 6-week Treatment in Patients With Acne Vulgaris [NCT00469755]Phase 4302 participants (Actual)Interventional2006-02-28Completed
Evaluation of the Effectiveness of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) in Reducing Antibiotic Sensitive and Resistant Strains of P Acnes [NCT00907101]Phase 430 participants (Actual)Interventional2009-06-30Completed
Factors Affecting Medication Adherence to Topical Acne Medications: a Single-center, Prospective Study Evaluating the Adherence and Patient Satisfaction to Single and Multiple Topical Acne Medications [NCT05582434]Early Phase 172 participants (Anticipated)Interventional2023-12-31Not yet recruiting
[NCT02651220]Phase 31,001 participants (Actual)Interventional2015-11-30Completed
A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris. [NCT02073448]Phase 3417 participants (Actual)Interventional2014-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00421993 (6) [back to overview]Percent Change in Total Lesion Counts
NCT00421993 (6) [back to overview]Percent Change in Noniflammatory Lesion Counts
NCT00421993 (6) [back to overview]Success Rate on the Investigator's Global Assessment
NCT00421993 (6) [back to overview]Percent Change in Inflammatory Lesion Counts
NCT00421993 (6) [back to overview]Changes in Inflammatory Lesion Counts
NCT00421993 (6) [back to overview]Changes in Noninflammatory Lesion Counts
NCT00446043 (7) [back to overview]Number of Participants With Local Tolerability Assessment For Dryness
NCT00446043 (7) [back to overview]Number of Participants With Local Tolerability Assessment For Erythema
NCT00446043 (7) [back to overview]Number of Participants With Local Tolerability Assessment For Scaling
NCT00446043 (7) [back to overview]Number of Participants With Local Tolerability Assessment For Stinging/Burning
NCT00446043 (7) [back to overview]Number of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)
NCT00446043 (7) [back to overview]Number of Participants With Clinically Significant Abnormal Laboratory Parameters
NCT00446043 (7) [back to overview]Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF
NCT00598832 (5) [back to overview]Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12
NCT00598832 (5) [back to overview]Mean Percent Change in Total Lesion Count From Baseline to Week 12
NCT00598832 (5) [back to overview]Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12
NCT00598832 (5) [back to overview]Co-Primary Endpoint: Absolute Change in Total Lesion Count From Baseline to Week 12
NCT00598832 (5) [back to overview]Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12
NCT00599521 (5) [back to overview]Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12
NCT00599521 (5) [back to overview]Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12
NCT00599521 (5) [back to overview]Co-Primary Endpoint: Absolute Change in Total Lesion Counts From Baseline to Week 12
NCT00599521 (5) [back to overview]Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12
NCT00599521 (5) [back to overview]Mean Percent Change in Total Lesion Count From Baseline to Week 12
NCT00647556 (5) [back to overview]Change From Baseline in Overall Integrated Assessment of Photodamage at Week 24
NCT00647556 (5) [back to overview]Number of Participants in Each Category of the Investigator Evaluation of Global Response (Improvement) at Week 12 and Week 24
NCT00647556 (5) [back to overview]Number of Participants in Each Category of the Subject Evaluation of Improvement at Week 12 and Week 24
NCT00647556 (5) [back to overview]Number of Participants Who Improved (a Decrease of at Least One Point) in Overall Integrated Assessment of Photodamage From Baseline to Week 12.
NCT00647556 (5) [back to overview]Photonumeric Scale for the Assessment of Photodamage From Baseline to Week 12 and Baseline to Week 24
NCT00660985 (9) [back to overview]Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 1 (AUC (0-24))
NCT00660985 (9) [back to overview]Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 30 (AUC (0-24))
NCT00660985 (9) [back to overview]Tmax (hr) at Day 30
NCT00660985 (9) [back to overview]Tmax (hr) at Day 15
NCT00660985 (9) [back to overview]Cmax (ng/mL) at Day 30
NCT00660985 (9) [back to overview]Cmax (ng/mL) at Day 15
NCT00660985 (9) [back to overview]Tmax (hr) at Day 1
NCT00660985 (9) [back to overview]Cmax (ng/mL) at Day 1
NCT00660985 (9) [back to overview]Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 15 (AUC (0-24))
NCT00671749 (7) [back to overview]Percent Change From Baseline in Total Lesion Counts
NCT00671749 (7) [back to overview]Global Assessment of Improvement From Baseline
NCT00671749 (7) [back to overview]Worst Post Baseline Tolerability Assessment - Erythema
NCT00671749 (7) [back to overview]Worst Post Baseline Tolerability Assessment - Dryness
NCT00671749 (7) [back to overview]Worst Post Baseline Tolerability Assessment - Scaling
NCT00671749 (7) [back to overview]Worst Post Baseline Tolerability Assessment - Burning/Stinging
NCT00671749 (7) [back to overview]Global Severity Assessment Success
NCT00687908 (5) [back to overview]Maintenance Success for Non-inflammatory Lesions at Week 24
NCT00687908 (5) [back to overview]Maintenance Success for Total Lesions at Week 24
NCT00687908 (5) [back to overview]Percent of Subjects With Adverse Events
NCT00687908 (5) [back to overview]Maintenance Success for Inflamatory Lesions at Week 24
NCT00687908 (5) [back to overview]Investigator Global Assessment (IGA) Maintenance Success at Week 24
NCT00688064 (5) [back to overview]Percent of Subjects With Adverse Events
NCT00688064 (5) [back to overview]Percent Change From Baseline in Total Lesion Counts at Week 12.
NCT00688064 (5) [back to overview]Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12
NCT00688064 (5) [back to overview]Percent Change From Baseline in Inflammatory Lesion Counts at Week 12.
NCT00688064 (5) [back to overview]Success Rate on the Investigator's Global Assessment
NCT00696449 (1) [back to overview]Adherence to Treatment
NCT00714714 (1) [back to overview]Assessment of Facial Irritation and Cutaneous Effects
NCT00807014 (11) [back to overview]Mean Percent Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Inflammatory, Non-inflammatory, and Total Lesion Counts
NCT00807014 (11) [back to overview]Mean Scores for Global Change in Acne Improvement at Weeks 1, 2, 4, 8, and 12 Compared to the Start of Treatment (Prior to Week 1)
NCT00807014 (11) [back to overview]Mean Scores for Self-evaluation of Acne Improvement at Weeks 1, 2, 4, 8, and 12 Compared to the Start of Treatment (Prior to Week 1)
NCT00807014 (11) [back to overview]Number of Participants in the Indicated Categories for Overall Tolerance at Week 12/Early Termination
NCT00807014 (11) [back to overview]Mean Change From Baseline to Week 12 for the Indicated Domain Scores and the Global Score of the Participant-completed Skindex-29 QoL Questionnaire
NCT00807014 (11) [back to overview]Mean Change From Baseline to Week 2 in the Global Score of the Participant-completed Skindex-29 Quality of Life (QoL) Questionnaire
NCT00807014 (11) [back to overview]Correlation Between Skindex-29 Questionnaire Scores and Total Lesion Counts From Baseline to Week 2
NCT00807014 (11) [back to overview]Mean Acne Grades at Baseline and Weeks 1, 2, 4, 8, and 12 Assessed by the Leeds Revised Acne Grading System
NCT00807014 (11) [back to overview]Mean Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Inflammatory, Non-inflammatory, and Total Lesion Counts
NCT00807014 (11) [back to overview]Mean Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Tolerance Symptoms of Itching and Burning
NCT00807014 (11) [back to overview]Mean Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Tolerance Symptoms of Peeling, Erythema, and Dryness
NCT00829049 (4) [back to overview]Median Percent Change From Baseline in the Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12
NCT00829049 (4) [back to overview]Median Percent Change From Baseline in Inflammatory Lesion Counts (Papules/Pustules, Nodules) at Week 16
NCT00829049 (4) [back to overview]Percentage of Patients With >= 2 Grade Improvement in the Overall Disease Severity Score at Week 12
NCT00829049 (4) [back to overview]Percentage of Patients With >= 1 Grade Improvement in the Investigator Global Assessment at Week 16
NCT00883233 (1) [back to overview]Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline.
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8
NCT00887484 (44) [back to overview]Irritant/Allergic Contact Dermatitis
NCT00887484 (44) [back to overview]Investigators Static Global Assessment
NCT00887484 (44) [back to overview]Inflammatory Acne Lesion Counts
NCT00887484 (44) [back to overview]Erythema (Redness)
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8
NCT00887484 (44) [back to overview]Erythema (Redness)
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2
NCT00887484 (44) [back to overview]Skin Peeling
NCT00887484 (44) [back to overview]Skin Dryness
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8
NCT00887484 (44) [back to overview]Total Acne Lesion Counts
NCT00887484 (44) [back to overview]Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2
NCT00887484 (44) [back to overview]Skin Peeling
NCT00887484 (44) [back to overview]Skin Dryness
NCT00887484 (44) [back to overview]Quality of Life Questionnaire - Global Score
NCT00887484 (44) [back to overview]Quality of Life Questionnaire - Functional Domain
NCT00887484 (44) [back to overview]Quality of Life Questionnaire - Emotional Domain
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Compliance at Week 8
NCT00887484 (44) [back to overview]Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2
NCT00887484 (44) [back to overview]Non-inflammatory Acne Lesion Counts
NCT00887484 (44) [back to overview]Irritant/Allergic Contact Dermatitis
NCT00907101 (5) [back to overview]Change From Baseline in Quantitative Bacteriology Measurements at Week 4
NCT00907101 (5) [back to overview]Worst Post Baseline Tolerability Assessment - Dryness
NCT00907101 (5) [back to overview]Worst Post Baseline Tolerability Assessment - Erythema
NCT00907101 (5) [back to overview]Worst Post Baseline Tolerability Assessment - Scaling
NCT00907101 (5) [back to overview]Worst Post Baseline Tolerability Assessment - Stinging/Burning
NCT00919191 (2) [back to overview]Comparative Assessment of Facial Irritation and Cutaneous Effects.
NCT00919191 (2) [back to overview]Self Assessment of Burning/Stinging and Itching
NCT00926367 (18) [back to overview]Skin Dryness
NCT00926367 (18) [back to overview]Self Assessment of Texture (Roughness)
NCT00926367 (18) [back to overview]Self Assessment of Stinging
NCT00926367 (18) [back to overview]Self Assessment of Pain
NCT00926367 (18) [back to overview]Self Assessment of Oiliness
NCT00926367 (18) [back to overview]Self Assessment of Dryness
NCT00926367 (18) [back to overview]Self Assessment of Crusting
NCT00926367 (18) [back to overview]Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?
NCT00926367 (18) [back to overview]Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?
NCT00926367 (18) [back to overview]Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?
NCT00926367 (18) [back to overview]Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?
NCT00926367 (18) [back to overview]Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?
NCT00926367 (18) [back to overview]Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?
NCT00926367 (18) [back to overview]Self Assessment of Blistering
NCT00926367 (18) [back to overview]Self Assessment of Burning
NCT00926367 (18) [back to overview]Skin Erythema (Redness)
NCT00926367 (18) [back to overview]Skin Moisture and Hydration
NCT00926367 (18) [back to overview]Skin Hydration
NCT00952523 (1) [back to overview]Facial Irritation and Cutaneous Effects
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Dryness
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Itching
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Redness
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Scaling
NCT00964223 (44) [back to overview]Erythema (Redness) Score
NCT00964223 (44) [back to overview]Erythema (Redness) Score
NCT00964223 (44) [back to overview]Inflammatory Acne Lesion Counts
NCT00964223 (44) [back to overview]Investigator Static Global Assessment Score
NCT00964223 (44) [back to overview]Irritant/Allergic Contact Dermatitis Score
NCT00964223 (44) [back to overview]Irritant/Allergic Contact Dermatitis Score
NCT00964223 (44) [back to overview]Non-Inflammatory Acne Lesion Counts
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Comfort of Skin
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Compliance
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Compliance
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Application of Product
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Burning
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Dryness
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Itching
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Redness
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Scaling
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With?
NCT00964223 (44) [back to overview]Skin Dryness Score
NCT00964223 (44) [back to overview]Skin Peeling Score
NCT00964223 (44) [back to overview]Skin Peeling Score
NCT00964223 (44) [back to overview]Skindex-29 Quality of Life Questionnaire - Emotional Domain
NCT00964223 (44) [back to overview]Skindex-29 Quality of Life Questionnaire - Functional Domain
NCT00964223 (44) [back to overview]Skindex-29 Quality of Life Questionnaire - Global Score
NCT00964223 (44) [back to overview]Skindex-29 Quality of Life Questionnaire - Symptomatic Domain
NCT00964223 (44) [back to overview]Total Acne Lesion Counts
NCT00964223 (44) [back to overview]Skin Dryness Score
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Comfort of Skin
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Comparison of Study Products to Products Used in the Past
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Application of Product
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product
NCT00964223 (44) [back to overview]Product Acceptability and Preference Questionnaire - Severity of Burning
NCT01014689 (2) [back to overview]Percent Change From Baseline in Total Lesion Count
NCT01014689 (2) [back to overview]Success Rate on the Investigator's Global Assessment (IGA) at Week 12
NCT01046396 (2) [back to overview]Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.
NCT01046396 (2) [back to overview]6 Question Subject Cosmetic Acceptability Questionnaire at Week 3
NCT01046565 (2) [back to overview]6 Question Subject Cosmetic Acceptability Questionnaire
NCT01046565 (2) [back to overview]Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.
NCT01138735 (4) [back to overview]Success Rate
NCT01138735 (4) [back to overview]Change From Baseline in Total Lesion Counts
NCT01138735 (4) [back to overview]Change in Inflammatory Lesion Counts From Baseline
NCT01138735 (4) [back to overview]Percent Change in Total Lesion Counts From Baseline
NCT01209949 (3) [back to overview]Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12
NCT01209949 (3) [back to overview]Number of Participants With Tolerability Assessments Resulting in an Adverse Event
NCT01209949 (3) [back to overview]Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12.
NCT01213199 (1) [back to overview]Global Scarring Severity
NCT01231334 (7) [back to overview]Change From Baseline in Global Acne Assessment Score (GAAS) at Week 12
NCT01231334 (7) [back to overview]Percent Change From Baseline in Inflammatory Lesion Counts at Week 12
NCT01231334 (7) [back to overview]Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12
NCT01231334 (7) [back to overview]Percent Change From Baseline in Total Lesion Count at Week 12
NCT01231334 (7) [back to overview]Percentage of Participants at Week 12 Having at Least a One Point Decrease in Overall Disease Severity
NCT01231334 (7) [back to overview]Percentage of Participants Demonstrating a ≥ 1 Category Increase in Tolerability From Baseline at Week 12
NCT01231334 (7) [back to overview]Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12
NCT01504204 (3) [back to overview]Change in Acne Lesion Count
NCT01504204 (3) [back to overview]Adherence to Study Medication
NCT01504204 (3) [back to overview]Change in Acne Global Assessment
NCT01910064 (6) [back to overview]Local Tolerability (Stinging/Burning)
NCT01910064 (6) [back to overview]Local Tolerability (Dryness)
NCT01910064 (6) [back to overview]Local Tolerability (Erythema)
NCT01910064 (6) [back to overview]Local Tolerability (Pruritus)
NCT01910064 (6) [back to overview]Local Tolerability (Scaling)
NCT01910064 (6) [back to overview]Percent Changes From Baseline in Total Lesion Counts
NCT01951417 (8) [back to overview]Total Lesion Count
NCT01951417 (8) [back to overview]Subject Questionnaire
NCT01951417 (8) [back to overview]Stinging/Burning
NCT01951417 (8) [back to overview]Scaling
NCT01951417 (8) [back to overview]Non-inflammatory Lesions
NCT01951417 (8) [back to overview]Inflammatory Lesions
NCT01951417 (8) [back to overview]Dryness
NCT01951417 (8) [back to overview]Erythema
NCT02073448 (7) [back to overview]Local Tolerability (Stinging/Burning)
NCT02073448 (7) [back to overview]Local Tolerability (Scaling)
NCT02073448 (7) [back to overview]Percent Changes From Baseline in Total Lesion Counts
NCT02073448 (7) [back to overview]Percent of Subjects With Adverse Events
NCT02073448 (7) [back to overview]Local Tolerability (Dryness)
NCT02073448 (7) [back to overview]Local Tolerability (Erythema)
NCT02073448 (7) [back to overview]Local Tolerability (Pruritus)
NCT02173054 (5) [back to overview]Skin Tolerability: Skin Sebum Content and Skin Hydration
NCT02173054 (5) [back to overview]Skin Tolerability: Transepidermal Water Loss (TEWL)
NCT02173054 (5) [back to overview]Reduction of Severity of Acne: Acne Severity Index (ASI)
NCT02173054 (5) [back to overview]Reduction of Severity of Acne
NCT02173054 (5) [back to overview]Reduction of Undesirable Effects
NCT02249104 (6) [back to overview]Percent Change From Baseline in Non-inflammatory Lesion Count
NCT02249104 (6) [back to overview]Percent Change From Baseline in Inflammatory Lesion Count
NCT02249104 (6) [back to overview]Mean Change From Baseline in Total Lesion Count
NCT02249104 (6) [back to overview]Mean Change From Baseline in Non-inflammatory Lesion Count
NCT02249104 (6) [back to overview]Mean Change From Baseline in Inflammatory Lesion Count
NCT02249104 (6) [back to overview]Percent Change From Baseline in Total Lesion Count
NCT02525549 (2) [back to overview]Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions
NCT02525549 (2) [back to overview]Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions
NCT02651220 (3) [back to overview]"Percentage of Patients With a Clinical Response of Clinical Success Using the Investigator's Global Assessment (IGA) at Week 12"
NCT02651220 (3) [back to overview]Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions.
NCT02651220 (3) [back to overview]Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions.
NCT02755545 (1) [back to overview]Percent Change From Baseline in Total Lesions at Week 12
NCT02899000 (11) [back to overview]Percent Change From Baseline in Total Lesion Count
NCT02899000 (11) [back to overview]Number and Percent of Adverse Events
NCT02899000 (11) [back to overview]Change in Number of Inflammatory Lesions
NCT02899000 (11) [back to overview]Subject Assessment of Acne Improvement
NCT02899000 (11) [back to overview]Change From Baseline in Inflammatory Lesion Count
NCT02899000 (11) [back to overview]Change From Baseline in Non-Inflammatory Lesion Count
NCT02899000 (11) [back to overview]Change From Baseline in Total Lesion Count
NCT02899000 (11) [back to overview]Investigator's Evaluation: Number of Subjects Not Considered to be Oral Isotretinoin Candidates
NCT02899000 (11) [back to overview]Number and Percent of Subjects With IGA Success
NCT02899000 (11) [back to overview]Percent Change From Baseline in Inflammatory Lesion Count
NCT02899000 (11) [back to overview]Percent Change From Baseline in Non-Inflammatory Lesion Count
NCT02932267 (1) [back to overview]Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire
NCT03393494 (2) [back to overview]Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count
NCT03393494 (2) [back to overview]Mean Percent Change From Baseline in the Papules and Pustules Lesion Count
NCT03457636 (4) [back to overview]IGA Score
NCT03457636 (4) [back to overview]Investigator Global Assessment (IGA) Score
NCT03457636 (4) [back to overview]Non-inflammatory Lesion Count
NCT03457636 (4) [back to overview]Inflammatory Lesion Count
NCT05096312 (2) [back to overview]Inflammatory Score
NCT05096312 (2) [back to overview]Global Acne Grading System Score

Percent Change in Total Lesion Counts

Percent Changes in Total Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100 (NCT00421993)
Timeframe: at week 12

InterventionPercent change (Mean)
Adapalene/Benzoyl Peroxide Gel-57.7
Adapalene Gel-47.5
Benzoyl Peroxide Gel-47.2
Gel Vehicle-35.2

[back to top]

Percent Change in Noniflammatory Lesion Counts

Percent Changes in Noninflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100 (NCT00421993)
Timeframe: at week 12

InterventionPercent change (Mean)
Adapalene/Benzoyl Peroxide Gel-55.6
Adapalene Gel-46.0
Benzoyl Peroxide Gel-44.1
Gel Vehicle-32.3

[back to top]

Success Rate on the Investigator's Global Assessment

"Percentage of subjects rated Clear and Almost Clear on 5-point scale (0=clear; 4=severe)" (NCT00421993)
Timeframe: at week 12

InterventionPercentage of participants (Number)
Adapalene/Benzoyl Peroxide Gel37.9
Adapalene Gel21.8
Benzoyl Peroxide Gel26.7
Gel Vehicle17.9

[back to top]

Percent Change in Inflammatory Lesion Counts

Percent Changes in Inflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100 (NCT00421993)
Timeframe: at week 12

InterventionPercent change (Mean)
Adapalene/Benzoyl Peroxide Gel-61.7
Adapalene Gel-50.1
Benzoyl Peroxide Gel-52.2
Gel Vehicle-40.8

[back to top]

Changes in Inflammatory Lesion Counts

Changes in Inflammatory Lesion Counts equals Week 12 Inflammatory Lesion Counts minus Baseline Inflammatory Lesion Counts (NCT00421993)
Timeframe: from Baseline to week 12

InterventionLesion count (Median)
Adapalene/Benzoyl Peroxide Gel-18
Adapalene Gel-15
Benzoyl Peroxide Gel-16
Gel Vehicle-12

[back to top]

Changes in Noninflammatory Lesion Counts

Change in Noninflammatory Lesion Counts equals Week 12 Noninflammatory Lesion Count minus Baseline Noninflammatory Lesion Count (NCT00421993)
Timeframe: from Baseline to week 12

InterventionLesion count (Median)
Adapalene/Benzoyl Peroxide Gel-28
Adapalene Gel-24
Benzoyl Peroxide Gel-23
Gel Vehicle-18

[back to top]

Number of Participants With Local Tolerability Assessment For Dryness

"Local tolerability assessment for dryness (brittle and/or tight sensation) was graded on a 0 (none) to 3 (severe) scale as follows; none (0- no dryness), mild (1- slight but definite roughness), moderate (2 -moderate roughness), severe (3- marked roughness)." (NCT00446043)
Timeframe: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

InterventionParticipants (Count of Participants)
Baseline72323857Week 172323857Week 272323857Month 172323857Month 272323857Month 472323857Month 672323857Month 872323857Month 1072323857Month 1272323857
1=Mild0=None2=Moderate3=Severe
Adapalene/Benzoyl Peroxide385
Adapalene/Benzoyl Peroxide65
Adapalene/Benzoyl Peroxide2
Adapalene/Benzoyl Peroxide195
Adapalene/Benzoyl Peroxide190
Adapalene/Benzoyl Peroxide35
Adapalene/Benzoyl Peroxide264
Adapalene/Benzoyl Peroxide152
Adapalene/Benzoyl Peroxide12
Adapalene/Benzoyl Peroxide1
Adapalene/Benzoyl Peroxide281
Adapalene/Benzoyl Peroxide121
Adapalene/Benzoyl Peroxide311
Adapalene/Benzoyl Peroxide109
Adapalene/Benzoyl Peroxide6
Adapalene/Benzoyl Peroxide337
Adapalene/Benzoyl Peroxide52
Adapalene/Benzoyl Peroxide320
Adapalene/Benzoyl Peroxide37
Adapalene/Benzoyl Peroxide4
Adapalene/Benzoyl Peroxide58
Adapalene/Benzoyl Peroxide278
Adapalene/Benzoyl Peroxide48
Adapalene/Benzoyl Peroxide3
Adapalene/Benzoyl Peroxide291
Adapalene/Benzoyl Peroxide36
Adapalene/Benzoyl Peroxide0

[back to top]

Number of Participants With Local Tolerability Assessment For Erythema

"Local tolerability assessment for erythema (abnormal redness of the skin) was graded on a 0 (none) to 3 (severe) scale as follows; none (0- no erythema), mild (1- slight pinkness present), moderate (2- definite redness, easily recognized), severe (3- intense redness). The worst severity scores were generally mild or moderate, and rarely severe." (NCT00446043)
Timeframe: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

InterventionParticipants (Count of Participants)
Baseline72323857Week 172323857Week 272323857Month 172323857Month 272323857Month 472323857Month 672323857Month 872323857Month 1072323857Month 1272323857
0 = None1 = Mild2=Moderate3=Severe
Adapalene/Benzoyl Peroxide348
Adapalene/Benzoyl Peroxide94
Adapalene/Benzoyl Peroxide10
Adapalene/Benzoyl Peroxide233
Adapalene/Benzoyl Peroxide157
Adapalene/Benzoyl Peroxide32
Adapalene/Benzoyl Peroxide1
Adapalene/Benzoyl Peroxide277
Adapalene/Benzoyl Peroxide133
Adapalene/Benzoyl Peroxide17
Adapalene/Benzoyl Peroxide2
Adapalene/Benzoyl Peroxide292
Adapalene/Benzoyl Peroxide105
Adapalene/Benzoyl Peroxide18
Adapalene/Benzoyl Peroxide320
Adapalene/Benzoyl Peroxide90
Adapalene/Benzoyl Peroxide16
Adapalene/Benzoyl Peroxide334
Adapalene/Benzoyl Peroxide48
Adapalene/Benzoyl Peroxide7
Adapalene/Benzoyl Peroxide296
Adapalene/Benzoyl Peroxide59
Adapalene/Benzoyl Peroxide6
Adapalene/Benzoyl Peroxide0
Adapalene/Benzoyl Peroxide276
Adapalene/Benzoyl Peroxide57
Adapalene/Benzoyl Peroxide8
Adapalene/Benzoyl Peroxide270
Adapalene/Benzoyl Peroxide56
Adapalene/Benzoyl Peroxide3
Adapalene/Benzoyl Peroxide284
Adapalene/Benzoyl Peroxide39
Adapalene/Benzoyl Peroxide4

[back to top]

Number of Participants With Local Tolerability Assessment For Scaling

"Local tolerability assessment for scaling (abnormal shedding of the stratum corneum) was graded on a 0 (none) to 3 (severe) scale as follow; none (0- no Scaling), mild (1- barely perceptible shedding, noticeable only on light scratching or rubbing), moderate (2- obvious but not profuse shedding), severe (3- heavy scale production)." (NCT00446043)
Timeframe: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

InterventionParticipants (Count of Participants)
Baseline72323857Week 172323857Week 272323857Month 172323857Month 272323857Month 472323857Month 672323857Month 872323857Month 1072323857Month 1272323857
0=None1=Mild2=Moderate3=Severe
Adapalene/Benzoyl Peroxide410
Adapalene/Benzoyl Peroxide41
Adapalene/Benzoyl Peroxide228
Adapalene/Benzoyl Peroxide164
Adapalene/Benzoyl Peroxide30
Adapalene/Benzoyl Peroxide1
Adapalene/Benzoyl Peroxide284
Adapalene/Benzoyl Peroxide130
Adapalene/Benzoyl Peroxide14
Adapalene/Benzoyl Peroxide312
Adapalene/Benzoyl Peroxide93
Adapalene/Benzoyl Peroxide10
Adapalene/Benzoyl Peroxide0
Adapalene/Benzoyl Peroxide338
Adapalene/Benzoyl Peroxide84
Adapalene/Benzoyl Peroxide4
Adapalene/Benzoyl Peroxide351
Adapalene/Benzoyl Peroxide330
Adapalene/Benzoyl Peroxide28
Adapalene/Benzoyl Peroxide3
Adapalene/Benzoyl Peroxide301
Adapalene/Benzoyl Peroxide38
Adapalene/Benzoyl Peroxide294
Adapalene/Benzoyl Peroxide33
Adapalene/Benzoyl Peroxide2
Adapalene/Benzoyl Peroxide308
Adapalene/Benzoyl Peroxide19

[back to top]

Number of Participants With Local Tolerability Assessment For Stinging/Burning

"Local tolerability assessment for stinging/burning [prickling pain sensation immediately after (within 5 minutes of) dosing] was graded on a 0 (none) to 3 (severe) scale as follows; none (0- no stinging/ burning), mild (1- slight warm, tingling/stinging sensation; not really bothersome), moderate (2- definite warm, tingling/stinging sensation that is somewhat), severe (3- hot, tingling/stinging sensation that has caused definite discomfort)." (NCT00446043)
Timeframe: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

InterventionParticipants (Count of Participants)
Baseline72323857Week 172323857Week 272323857Month 172323857Month 272323857Month 472323857Month 672323857Month 872323857Month 1072323857Month 1272323857
2=Moderate3=Severe0=None1=Mild
Adapalene/Benzoyl Peroxide440
Adapalene/Benzoyl Peroxide10
Adapalene/Benzoyl Peroxide201
Adapalene/Benzoyl Peroxide154
Adapalene/Benzoyl Peroxide63
Adapalene/Benzoyl Peroxide319
Adapalene/Benzoyl Peroxide84
Adapalene/Benzoyl Peroxide21
Adapalene/Benzoyl Peroxide331
Adapalene/Benzoyl Peroxide66
Adapalene/Benzoyl Peroxide14
Adapalene/Benzoyl Peroxide373
Adapalene/Benzoyl Peroxide42
Adapalene/Benzoyl Peroxide364
Adapalene/Benzoyl Peroxide2
Adapalene/Benzoyl Peroxide0
Adapalene/Benzoyl Peroxide337
Adapalene/Benzoyl Peroxide20
Adapalene/Benzoyl Peroxide4
Adapalene/Benzoyl Peroxide312
Adapalene/Benzoyl Peroxide23
Adapalene/Benzoyl Peroxide5
Adapalene/Benzoyl Peroxide1
Adapalene/Benzoyl Peroxide303
Adapalene/Benzoyl Peroxide22
Adapalene/Benzoyl Peroxide306
Adapalene/Benzoyl Peroxide19

[back to top]

Number of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00446043)
Timeframe: Baseline up to Month 14

InterventionParticipants (Count of Participants)
Participants (N) With At least one AEParticipants (N) With At Least one SAE
Adapalene/Benzoyl Peroxide2885

[back to top]

Number of Participants With Clinically Significant Abnormal Laboratory Parameters

Clinical laboratory parameters included hematology, blood chemistry, urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported. (NCT00446043)
Timeframe: Baseline up to Month 14

InterventionParticipants (Count of Participants)
HematologyBlood ChemistryUrine Analysis
Adapalene/Benzoyl Peroxide000

[back to top]

Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF

Percent change in inflammatory, noninflammatory and total lesions at Month 12 was measured from baseline lesions. The noninflammatory lesion count was the sum of open comedones (a mass of sebaceous material that is impacted behind an open follicular orifice (blackhead) and closed comedones (a mass of sebaceous material that is impacted behind a closed follicular orifice (whitehead). The inflammatory lesion count was the sum of papules (a small, solid elevation less than 1.0 cm in diameter) and pustules (a small, circumscribed elevation of the skin that contains yellow-white exudate). The total lesion count was the sum of inflammatory and noninflammatory lesions. Missing adapalene and benzoyl peroxide data were imputed using last observation carried forward (LOCF). (NCT00446043)
Timeframe: Baseline, Month 12 LOCF

Interventionpercent change (Mean)
Inflammatory Lesion CountsNoninflammatory Lesion CountsTotal Lesion Counts
Adapalene/Benzoyl Peroxide-59.70-58.80-58.85

[back to top]

Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12

(NCT00598832)
Timeframe: Baseline to Week 12

InterventionAbsolute Change in Non-Infl Lesion count (Least Squares Mean)
Adapalene Lotion 0.1%22.4
Adapalene Lotion Vehicle 0%15.3

[back to top]

Mean Percent Change in Total Lesion Count From Baseline to Week 12

Percent change in lesion count from baseline to week 12 (NCT00598832)
Timeframe: From Baseline to Week 12

,
Intervention% Change in Lesion Count (Mean)
Total lesion countInflammatoryNon-Inflammatory
Adapalene Lotion 0.1%-51.5-54.9-49.6
Adapalene Lotion Vehicle 0%-37.1-40.3-35.7

[back to top]

Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12

"Success defined as percentage of subjects who achieved at least a two-grade reduction in IGA scale (e.g from moderate to clear or almost clear)at week 12 from baseline, Last Observation Carried Forward, Intent to treat population. The IGA (Investigator Global Assessment) is defined as a 5 point scale (0 to 4). 0 = clear , 1= almost clear, 2= mild, 3= moderate, 4=severe." (NCT00598832)
Timeframe: From Baseline to Week 12

InterventionPercentage of Participants (Number)
Adapalene Lotion 0.1%26.3
Adapalene Lotion Vehicle 0%17.3

[back to top]

Co-Primary Endpoint: Absolute Change in Total Lesion Count From Baseline to Week 12

(NCT00598832)
Timeframe: Baseline to Week 12

InterventionAbsolute Change in Total Lesion Count (Least Squares Mean)
Adapalene Lotion 0.1%36.7
Adapalene Lotion Vehicle 0%25.5

[back to top]

Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12

(NCT00598832)
Timeframe: Baseline to Week 12

InterventionAbsolute Change in Infl Lesion count (Least Squares Mean)
Adapalene Lotion 0.1%14.3
Adapalene Lotion Vehicle 0%10.2

[back to top]

Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12

(NCT00599521)
Timeframe: Baseline to Week 12

InterventionAbsolute Change in Infl Lesion count (Least Squares Mean)
Adapalene Lotion 0.1%13.0
Adapalene Lotion Vehicle 0%10.4

[back to top]

Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12

(NCT00599521)
Timeframe: Baseline to Week 12

InterventionAbsolute Change in Non-Infl Lesion (Least Squares Mean)
Adapalene Lotion 0.1%19.5
Adapalene Lotion Vehicle 0%12.9

[back to top]

Co-Primary Endpoint: Absolute Change in Total Lesion Counts From Baseline to Week 12

(NCT00599521)
Timeframe: Baseline to 12 weeks

InterventionAbsolute Change in Total Lesion Count (Least Squares Mean)
Adapalene Lotion 0.1%32.5
Adapalene Lotion Vehicle 0%23.3

[back to top]

Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12

"Success defined as percentage of subjects who achieved at least a two-grade reduction in IGA scale (e.g from moderate to clear or almost clear)at week 12 from baseline, Last Observation Carried Forward, Intent to treat population. The IGA (Investigator Global Assessment) is defined as a 5 point scale (0 to 4). 0 = clear , 1= almost clear, 2= mild, 3= moderate, 4=severe." (NCT00599521)
Timeframe: From Baseline to Week 12

InterventionPercentage of Participants (Number)
Adapalene Lotion 0.1%24.1
Adapalene Lotion Vehicle 0%16.4

[back to top]

Mean Percent Change in Total Lesion Count From Baseline to Week 12

Percent change in lesion count from baseline to week 12 (NCT00599521)
Timeframe: From Baseline to 12 weeks

,
Intervention% Change in Lesion Count (Mean)
Total lesion countInflammatoryNon-Inflammatory
Adapalene Lotion 0.1%-44.6-46.0-43.1
Adapalene Lotion Vehicle 0%-32.8-36.9-30.2

[back to top]

Change From Baseline in Overall Integrated Assessment of Photodamage at Week 24

Number of participants who improved (a decrease by at least one point) in Overall Integrated Assessment of Photodamage from baseline to week 24. Overall Integrated Assessment of Photodamage is a scale from 0 - 5 (0 = None, 1 = Minimal, 2 = Mild, 3 - Moderate, 4 = Severe and 5 = Very Severe) with 0 being best and 5 being worst. (NCT00647556)
Timeframe: baseline to week 24

Interventionparticipants (Number)
Differin® Gel, 0.3%6
Tretinoin Emollient Cream10

[back to top]

Number of Participants in Each Category of the Investigator Evaluation of Global Response (Improvement) at Week 12 and Week 24

Number of participants in each category of the Investigator Evaluation of Global Response (Improvement) at week 12 and week 24. Investigator Evaluation of Global Response (Improvement) is evaluated on a scale from 0 - 6 (0 = Complete Response, 1 = Almost Complete (~90%) Response, 2 = Marked (~75%) Response, 3 = Moderate (~50%) Response, 4 = Slight (~25%) Response, 5 = No Response and 6 = Worsening) with 0 being best and 6 being worst. (NCT00647556)
Timeframe: week 12 and week 24

,
Interventionparticipants (Number)
week 12 Complete Responseweek 12 Almost Complete Responseweek 12 Marked Responseweek 12 Moderate Responseweek 12 Slight Responseweek 12 No Responseweek 12 Worseningweek 12 Missingweek 24 Complete Responseweek 24 Almost Complete Responseweek 24 Marked Responseweek 24 Moderate Responseweek 24 Slight Responseweek 24 No Responseweek 24 Worseningweek 24 Missing
Differin® Gel, 0.3%0002910300226203
Tretinoin Emollient Cream0014620200084300

[back to top]

Number of Participants in Each Category of the Subject Evaluation of Improvement at Week 12 and Week 24

Number of participants in each category of the Subject Evaluation of Improvement at week 12 and week 24. Subject Evaluation of Improvement was evaluated on a scale from 0 - 6 (0 = Complete Improvement, 1 = Almost (~90%) Improvement, 2 = Marked (~75%) Improvement, 3 = Moderate (~50%) Improvement, 4 = Slight (~25%) Improvement, 5 = No Change, 6 = Worse) with 0 being best and 6 being worst. (NCT00647556)
Timeframe: week 12 and week 24

,
Interventionparticipants (Number)
week 12 Complete Improvementweek 12 Almost Complete Improvementweek 12 Marked Improvementweek 12 Moderate Improvementweek 12 Slight Improvementweek 12 No Changeweek 12 Worseweek 12 Missingweek 24 Complete Improvementweek 24 Almost Complete Improvementweek 24 Marked Improvementweek 24 Moderate Improvementweek 24 Slight Improvementweek 24 No Changeweek 24 Worseweek 24 Missing
Differin® Gel, 0.3%0044400303243003
Tretinoin Emollient Cream0025420201441500

[back to top]

Number of Participants Who Improved (a Decrease of at Least One Point) in Overall Integrated Assessment of Photodamage From Baseline to Week 12.

Number of participants who improved in Overall Integrated Assessment of Photodamage from baseline to week 12. Overall Integrated Assessment of Photodamage was evaluated on a scale from 0 - 5 (0 = None, 1 = Minimal, 2 = Mild, 3 = Moderate 4 = Severe and 5 = Very Severe) with 0 being best and 5 being worst. (NCT00647556)
Timeframe: baseline to week 12

Interventionparticipants (Number)
Differin® Gel, 0.3%6
Tretinoin Emollient Cream4

[back to top]

Photonumeric Scale for the Assessment of Photodamage From Baseline to Week 12 and Baseline to Week 24

Number of participants in each category of the Photonumeric Scale for the Assessment of Photodamage from baseline to week 12 and baseline to week 24. Photonumeric Scale consisted of 9 categories (Fine Wrinkling, Mottled Pigmentation, Irregular Depigmentation, Lentigines, Coarse Wrinkling, Elastosis, Tactile Roughness, Telangiectasia, and Actinic Keratosis. These were evaluated on a scale from 0 - 4 (0 = None, 1 = Minimal, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst. (NCT00647556)
Timeframe: baseline, week 12 and week 24

,
Interventionparticipants (Number)
Fine wrinkling baseline None (0)Fine wrinkling baseline Minimal (1)Fine wrinkling baseline Mild (2)Fine wrinkling baseline Moderate (3)Fine wrinkling baseline Severe (4)Fine wrinkling week 12 None (0)Fine wrinkling week 12 Minimal (1)Fine wrinkling week 12 Mild (2)Fine wrinkling week 12 Moderate (3)Fine wrinkling week 12 Severe (4)Fine wrinkling week 24 None (0)Fine wrinkling week 24 Minimal (1)Fine wrinkling week 24 Mild (2)Fine wrinkling week 24 Moderate (3)Fine wrinkling week 24 Severe (4)Mottled pigmentation baseline None (0)Mottled pigmentation baseline Minimal (1)Mottled pigmentation baseline Mild (2)Mottled pigmentation baseline Moderate (3)Mottled pigmentation baseline Severe (4)Mottled pigmentation week 12 None (0)Mottled pigmentation week 12 Minimal (1)Mottled pigmentation week 12 Mild (2)Mottled pigmentation week 12 Moderate (3)Mottled pigmentation week 12 Severe (4)Mottled pigmentation week 24 None (0)Mottled pigmentation week 24 Minimal (1)Mottled pigmentation week 24 Mild (2)Mottled pigmentation week 24 Moderate (3)Mottled pigmentation week 24 Severe (4)Irregular depigmentation baseline None (0)Irregular depigmentation baseline Minimal (1)Irregular depigmentation baseline Mild (2)Irregular depigmentation baseline Moderate (3)Irregular depigmentation baseline Severe (4)Irregular depigmentation week 12 None (0)Irregular depigmentation week 12 Minimal (1)Irregular depigmentation week 12 Mild (2)Irregular depigmentation week 12 Moderate (3)Irregular depigmentation week 12 Severe (4)Irregular depigmentation week 24 None (0)Irregular depigmentation week 24 Minimal (1)Irregular depigmentation week 24 Mild (2)Irregular depigmentation week 24 Moderate (3)Irregular depigmentation week 24 Severe (4)Lentigines baseline None (0)Lentigines baseline Minimal (1)Lentigines baseline Mild (2)Lentigines baseline Moderate (3)Lentigines baseline Severe (4)Lentigines week 12 None (0)Lentigines week 12 Minimal (1)Lentigines week 12 Mild (2)Lentigines week 12 Moderate (3)Lentigines week 12 Severe (4)Lentigines week 24 None (0)Lentigines week 24 Minimal (1)Lentigines week 24 Mild (2)Lentigines week 24 Moderate (3)Lentigines week 24 Severe (4)Coarse wrinkling baseline None (0)Coarse wrinkling baseline Minimal (1)Coarse wrinkling baseline Mild (2)Coarse wrinkling baseline Moderate (3)Coarse wrinkling baseline Severe (4)Coarse wrinkling week 12 None (0)Coarse wrinkling week 12 Minimal (1)Coarse wrinkling week 12 Mild (2)Coarse wrinkling week 12 Moderate (3)Coarse wrinkling week 12 Severe (4)Coarse wrinkling week 24 None (0)Coarse wrinkling week 24 Minimal (1)Coarse wrinkling week 24 Mild (2)Coarse wrinkling week 24 Moderate (3)Coarse wrinkling week 24 Severe (4)Elastosis baseline None (0)Elastosis baseline Minimal (1)Elastosis baseline Mild (2)Elastosis baseline Moderate (3)Elastosis baseline Severe (4)Elastosis week 12 None (0)Elastosis week 12 Minimal (1)Elastosis week 12 Mild (2)Elastosis week 12 Moderate (3)Elastosis week 12 Severe (4)Elastosis week 24 None (0)Elastosis week 24 Minimal (1)Elastosis week 24 Mild (2)Elastosis week 24 Moderate (3)Elastosis week 24 Severe (4)Tactile Roughness baseline None (0)Tactile Roughness baseline Minimal (1)Tactile Roughness baseline Mild (2)Tactile Roughness baseline Moderate (3)Tactile Roughness baseline Severe (4)Tactile Roughness week 12 None (0)Tactile Roughness week 12 Minimal (1)Tactile Roughness week 12 Mild (2)Tactile Roughness week 12 Moderate (3)Tactile Roughness week 12 Severe (4)Tactile Roughness week 24 None (0)Tactile Roughness week 24 Minimal (1)Tactile Roughness week 24 Mild (2)Tactile Roughness week 24 Moderate (3)Tactile Roughness week 24 Severe (4)Telangiectasia baseline None (0)Telangiectasia baseline Minimal (1)Telangiectasia baseline Mild (2)Telangiectasia baseline Moderate (3)Telangiectasia baseline Severe (4)Telangiectasia week 12 None (0)Telangiectasia week 12 Minimal (1)Telangiectasia week 12 Mild (2)Telangiectasia week 12 Moderate (3)Telangiectasia week 12 Severe (4)Telangiectasia week 24 None (0)Telangiectasia week 24 Minimal (1)Telangiectasia week 24 Mild (2)Telangiectasia week 24 Moderate (3)Telangiectasia week 24 Severe (4)Actinic keratosis baseline None (0)Actinic keratosis baseline Minimal (1)Actinic keratosis baseline Mild (2)Actinic keratosis baseline Moderate (3)Actinic keratosis baseline Severe (4)Actinic keratosis week 12 None (0)Actinic keratosis week 12 Minimal (1)Actinic keratosis week 12 Mild (2)Actinic keratosis week 12 Moderate (3)Actinic keratosis week 12 Severe (4)Actinic keratosis week 24 None (0)Actinic keratosis week 24 Minimal (1)Actinic keratosis week 24 Mild (2)Actinic keratosis week 24 Moderate (3)Actinic keratosis week 24 Severe (4)
Differin® Gel, 0.3%00312001950028500078001761136411563016620175200257103750137400110220292202832017610194102103007341095010104010069002481034718511095001122001
Tretinoin Emollient Cream002112014911247104821075300104101752019410195000392105910077100057300843026430158101671038311473016701111300045420455105361931209420085200

[back to top]

Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 1 (AUC (0-24))

area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24 hr (corresponding to the dosing interval) (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)

Interventionng*h/mL (Mean)
Differin® Gel, 0.3%1.54
Differin® Gel, 0.1%0.31

[back to top]

Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 30 (AUC (0-24))

area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval) (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T72hr (post dose)

Interventionng*h/mL (Mean)
Differin® Gel, 0.3%2.64
Differin® Gel, 0.1%0.42

[back to top]

Tmax (hr) at Day 30

the time at which Cmax occurs (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T72hr (post dose)

Interventionhours (Mean)
Differin® Gel, 0.3%13
Differin® Gel, 0.1%12

[back to top]

Tmax (hr) at Day 15

the time at which Cmax occurs (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)

Interventionhours (Mean)
Differin® Gel, 0.3%13
Differin® Gel, 0.1%11

[back to top]

Cmax (ng/mL) at Day 30

the observed peak drug (adapalene) concentration (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T 72hr (post dose)

Interventionng/mL (Mean)
Differin® Gel, 0.3%0.15
Differin® Gel, 0.1%0.03

[back to top]

Cmax (ng/mL) at Day 15

the observed peak drug (adapalene) concentration (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)

Interventionng/mL (Mean)
Differin® Gel, 0.3%0.18
Differin® Gel, 0.1%0.04

[back to top]

Tmax (hr) at Day 1

the time at which Cmax occurs (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)

Interventionhours (Mean)
Differin® Gel, 0.3%15
Differin® Gel, 0.1%11

[back to top]

Cmax (ng/mL) at Day 1

the observed peak drug (adapalene) concentration (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)

Interventionng/mL (Mean)
Differin® Gel, 0.3%0.10
Differin® Gel, 0.1%0.02

[back to top]

Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 15 (AUC (0-24))

area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval) (NCT00660985)
Timeframe: T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)

Interventionng*h/mL (Mean)
Differin® Gel, 0.3%2.84
Differin® Gel, 0.1%0.50

[back to top]

Percent Change From Baseline in Total Lesion Counts

(NCT00671749)
Timeframe: 6 and 12 weeks

InterventionPercent Change (Mean)
Week 6Week 12
Combination Therapy-47-64

[back to top]

Global Assessment of Improvement From Baseline

(NCT00671749)
Timeframe: 12 weeks

Interventionparticipants (Number)
ClearAlmost ClearMarked ImprovementModerate ImprovementMinimal ImprovementNo ChangeWorse
Combination Therapy3402716581

[back to top]

Worst Post Baseline Tolerability Assessment - Erythema

"Please Note: Tolerability Assessments were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF." (NCT00671749)
Timeframe: 12 weeks

Interventionparticipants (Number)
NoneMildModerateSevere
Combination Therapy2937330

[back to top]

Worst Post Baseline Tolerability Assessment - Dryness

"Please Note: Tolerability Assessments were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF." (NCT00671749)
Timeframe: 12 weeks

Interventionparticipants (Number)
NoneMildModerateSevere
Combination Therapy4927203

[back to top]

Worst Post Baseline Tolerability Assessment - Scaling

"Please Note: Tolerability Assessments were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF." (NCT00671749)
Timeframe: 12 weeks

Interventionparticipants (Number)
NoneMildModerateSevere
Combination Therapy5327163

[back to top]

Worst Post Baseline Tolerability Assessment - Burning/Stinging

"Please Note: Tolerability Assessments were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF." (NCT00671749)
Timeframe: 12 weeks

Interventionparticipants (Number)
NoneMildModerateSevere
Combination Therapy671895

[back to top]

Global Severity Assessment Success

Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear (NCT00671749)
Timeframe: 6 and 12 weeks

Interventionparticipants (Number)
Week 6Week 12
Combination Therapy842

[back to top]

Maintenance Success for Non-inflammatory Lesions at Week 24

Maintenance success for non-inflamatory lesions at Week 24 is defined as the percentage of subjects maintaining at least 50 percent of the improvement obtained with prior combination therapy, in terms of non-inflamatory lesion counts. (NCT00687908)
Timeframe: Week 24

Interventionpercent of subjects (Number)
Adapalene-BPO78
Vehicle43.3

[back to top]

Maintenance Success for Total Lesions at Week 24

Maintenance success for total lesions at Week 24 is defined as the percentage of subjects maintaining at least 50 percent of the improvement obtained with prior combination therapy, in terms of total lesion counts. (NCT00687908)
Timeframe: Week 24

Interventionpercent of subjects (Number)
Adapalene-BPO78.9
Vehicle45.8

[back to top]

Percent of Subjects With Adverse Events

All participants with events were measured for that particular Outcome Measure and not only the events with a frequency threshold above 2 percent (NCT00687908)
Timeframe: Up to 24 weeks

Interventionpercent of subjects (Number)
Adapalene-BPO41.5
Vehicle29.2

[back to top]

Maintenance Success for Inflamatory Lesions at Week 24

Maintenance success for inflamatory lesions at Week 24 is defined as the percentage of subjects maintaining at least 50 percent of the improvement obtained with prior combination therapy, in terms of inflamatory lesion counts. (NCT00687908)
Timeframe: Week 24

Interventionpercent of subjects (Number)
Adapalene-BPO78
Vehicle48.3

[back to top]

Investigator Global Assessment (IGA) Maintenance Success at Week 24

"IGA maintenance success is defined as the percentage of subjects with IGA grade inferior or equal to Baseline IGA grade.~IGA grade:~0 Clear:Residual hyperpigmentation & erythema may be present~Almost Clear:A few scattered comedones & a few small papules.~Mild:Some comedones & some papules and pustules. No nodules present~Moderate:Many comedones, papules & pustules. One nodule may be present~Severe:Covered with comedones, numerous papules & pustules & few nodules & cysts may be present~Very severe:Highly inflammatory acne covering the face; with nodules & cysts present" (NCT00687908)
Timeframe: Baseline, Week 24

Interventionpercent of subjects (Number)
Adapalene-BPO70.7
Vehicle34.2

[back to top]

Percent of Subjects With Adverse Events

Percent of subjects with Adverse Events all along the study (up to 12 weeks follow-up period) (NCT00688064)
Timeframe: Up to 12 weeks

Intervention% of subjects (Number)
Adapalene-BPO + Doxycycline26.3
Vehicle + Doxycycline26.9

[back to top]

Percent Change From Baseline in Total Lesion Counts at Week 12.

(NCT00688064)
Timeframe: Week 12

Intervention% of change (Median)
Adapalene-BPO + Doxycycline-64
Vehicle + Doxycycline-41

[back to top]

Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12

(NCT00688064)
Timeframe: Week 12

Intervention% of change (Median)
Adapalene-BPO + Doxycycline-61
Vehicle + Doxycycline-40

[back to top]

Percent Change From Baseline in Inflammatory Lesion Counts at Week 12.

(NCT00688064)
Timeframe: Week 12

Intervention% of change (Median)
Adapalene-BPO + Doxycycline-72
Vehicle + Doxycycline-48

[back to top]

Success Rate on the Investigator's Global Assessment

"Percentage of subjects graded Clear or Almost Clear on 6-point IGA scale(0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe and 5=very severe)at week 12" (NCT00688064)
Timeframe: Week 12

Intervention% of subjects (Number)
Adapalene-BPO + Doxycycline31.5
Vehicle + Doxycycline8.4

[back to top]

Adherence to Treatment

Percentage of prescribed doses taken over the 12-week study period, as measured by a Medication Event Monitoring System (MEMS) cap (NCT00696449)
Timeframe: 12 weeks

InterventionPercent of prescribed doses (Median)
Frequent Office Visits64
Electronic Reminders38
Parental Reminders28
Standard of Care Control52

[back to top]

Assessment of Facial Irritation and Cutaneous Effects

Cumulative daily weekday scores for two weeks on Expert Grader Assessments: Dryness (0-8, none-deep)and Erythema (0-8, none-severe) and Self-Assessments: Burning/Stinging (0-3, none-severe) and Itching (0-3, none-severe) (NCT00714714)
Timeframe: cumulative daily weekday scores for two weeks

,
InterventionOrdinal data treated as interval (Mean)
Erythema (cumulative scores on a scale)Dryness (cumulative scores on a scale)Burning/Stinging (cumulative scores on a scale)Itching (cumulative scores on a scale)
Adapalene4.88.82.01.4
Tretinoin3.96.72.40.8

[back to top]

Mean Percent Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Inflammatory, Non-inflammatory, and Total Lesion Counts

Lesions were counted on the entire face (defined as the area from the upper part of the jaw to the lower part of the hairline), excluding maculae and non-inflammatory lesions located on the nose or chin. Inflammatory lesions (IL) included papules, pustules, nodules, and cysts. Non-inflammatory lesions (NIL) included closed comedones (whiteheads) and open comedones (blackheads). Total lesion count was calculated as the sum of IL and NIL. Percent change from Baseline was calculated as the values at Weeks 1, 2, 4, 8, and 12 minus the value at Baseline divided by Baseline value * 100. (NCT00807014)
Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 8, and 12

,
Interventionpercent change in lesions (Mean)
Non-inflammatory Lesions, Week 1, n=74, 73Non-inflammatory Lesions, Week 2, n=74, 73Non-inflammatory Lesions, Week 4, n=74, 73Non-inflammatory Lesions, Week 8, n=74, 73Non-inflammatory Lesions, Week 12, n=74, 73Inflammatory Lesions, Week 1, n=82, 84Inflammatory Lesions, Week 2, n=82, 84Inflammatory Lesions, Week 4, n=82, 84Inflammatory Lesions, Week 8, n=82, 84Inflammatory Lesions, Week 12, n=82, 84Total Lesions, Week 1, n=83, 85Total Lesions, Week 2, n=83, 85Total Lesions, Week 4, n=83, 85Total Lesions, Week 8, n=83, 85Total Lesions, Week 12, n=83, 85
Differin Gel-22.9-26.5-36.4-32.8-45.5-21.0-36.4-38.3-33.8-46.5-22.6-33.6-38.5-35.2-47.7
Duac Gel-29.8-38.4-52.6-59.5-69.7-36.8-53.0-67.9-67.6-72.4-32.1-46.3-59.6-65.7-73.0

[back to top]

Mean Scores for Global Change in Acne Improvement at Weeks 1, 2, 4, 8, and 12 Compared to the Start of Treatment (Prior to Week 1)

Global change in acne improvement was assessed by the investigator on a 7-point scale: 1=greatly worsened, 2=significantly worsened, 3=slightly worsened, 4=no change, 5=slightly improved, 6=significantly improved, or 7=greatly improved. Global change at the indicated week was assessed in terms of change from the previous week. Change at Week 2, for example, was an assessment of change from Week 1. (NCT00807014)
Timeframe: Start of treatment and Weeks 1, 2, 4, 8, and 12

,
Interventionscores on a scale (Mean)
Week 1, n=82, 82Week 2, n=82, 83Week 4, n=82, 83Week 8, n=82, 83Week 12, n=82, 84
Differin Gel4.95.35.35.15.5
Duac Gel5.25.45.75.86.0

[back to top]

Mean Scores for Self-evaluation of Acne Improvement at Weeks 1, 2, 4, 8, and 12 Compared to the Start of Treatment (Prior to Week 1)

Participants self-evaluated their acne improvement on a 3-point scale: 1=worsened, 2=no changes, and 3=improved. (NCT00807014)
Timeframe: Start of treatment and Weeks 1, 2, 4, 8, and 12

,
Interventionscores on a scale (Mean)
Week 1, n=82, 82Week 2, n=82, 83Week 4, n=82, 83Week 8, n=82, 83Week 12, n=82, 84
Differin Gel2.52.72.72.52.6
Duac Gel2.82.82.72.82.8

[back to top]

Number of Participants in the Indicated Categories for Overall Tolerance at Week 12/Early Termination

Participants were evaluated for overall tolerance to study drug by the investigator at the end of the study (Week 12 or Early Termination). Participants were given the tolerance grades of poor, fair, good, or excellent. (NCT00807014)
Timeframe: Week 12 or Early Termination

,
Interventionparticipants (Number)
PoorFairGoodExcellent
Differin Gel5144717
Duac Gel044234

[back to top]

Mean Change From Baseline to Week 12 for the Indicated Domain Scores and the Global Score of the Participant-completed Skindex-29 QoL Questionnaire

Skindex-29 is a self-administered QoL questionnaire comprised of 29 items scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 items), symptomatic (7 items), and functional (12 items), with domain scores ranging from 0 to 40, 28, and 48, respectively. Lower scores = better QoL. A Global Score (range 0-100) was derived by multiplying the sum of the points for all 29 items by a constant (0.862). Change from Baseline was calculated as the value at Week 2 minus the value at Baseline (Week 0). (NCT00807014)
Timeframe: Baseline (Week 0) and Week 12

,
Interventionscores on a scale (Mean)
Symptomatic DomainEmotional DomainFunctional DomainGlobal Score
Differin Gel-2.8-5.4-0.1-2.6
Duac Gel-7.4-10.3-3.5-6.8

[back to top]

Mean Change From Baseline to Week 2 in the Global Score of the Participant-completed Skindex-29 Quality of Life (QoL) Questionnaire

Skindex-29 is a self-administered QoL questionnaire comprised of 29 items scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 items), symptomatic (7 items), and functional (12 items), with domain scores ranging from 0 to 40, 28, and 48, respectively. Lower scores = better QoL. A Global Score (range 0-100) was derived by multiplying the sum of the points for all 29 items by a constant (0.862). Change from Baseline was calculated as the value at Week 2 minus the value at Baseline (Week 0). (NCT00807014)
Timeframe: Baseline (Week 0) and Week 2

Interventionscores on a scale (Mean)
Duac Gel-4.9
Differin Gel-1.1

[back to top]

Correlation Between Skindex-29 Questionnaire Scores and Total Lesion Counts From Baseline to Week 2

Analyses were performed to determine whether there was a correlation between the total lesion count and either the global or subdomain Skindex-29 questionnaire scores. Correlations between the Skindex-29 questionnaire scores and total lesion count from Baseline to Week 2 were assessed using Spearman's correlation coefficients, which ranges from -1 to 1. A score of 0 denotes no correlation, a score approaching 1 denotes correlation, and a score approaching -1 denotes inverse correlation. (NCT00807014)
Timeframe: Baseline (Week 0) and Week 2

,
InterventionCorrelation coefficient (Number)
Functional DomainSymptomatic DomainEmotional DomainGlobal Score
Differin Gel-0.0940.002-0.137-0.087
Duac Gel0.0420.1660.2370.223

[back to top]

Mean Acne Grades at Baseline and Weeks 1, 2, 4, 8, and 12 Assessed by the Leeds Revised Acne Grading System

The acne grade on the participant's face was assessed by the investigator using the LRAG, a photographic scale allowing for the assessment of the clinical status for acne severity for the face, back, and chest. It consists of a 12-grade scale (1, least severe; 12, most severe) for inflammatory visible lesions (les.). For non-inflammatory les., this scale comprises 3 photos of les. of increasing severity (grades 1-3). The scale provides a qualitative assessment of superficial/visible les. and provides consistency and inter-/intra-rater reliability. Grading was performed prior to les. counting. (NCT00807014)
Timeframe: Baseline (Week 0); Weeks 1, 2, 4, 8, and 12

,
Interventionscores on a scale (Mean)
Baseline (Week 0)Week 1Week 2Week 4Week 8Week 12
Differin Gel2.62.32.11.91.91.6
Duac Gel2.72.42.01.71.61.2

[back to top]

Mean Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Inflammatory, Non-inflammatory, and Total Lesion Counts

Lesions were counted on the entire face (defined as the area from the upper part of the jaw to the lower part of the hairline), excluding maculae and non-inflammatory lesions located on the nose or chin. Inflammatory lesions included papules, pustules, nodules, and cysts. Non-inflammatory lesions included closed comedones (whiteheads) and open comedones (blackheads). The total lesion count was calculated as the sum of inflammatory and non-inflammatory lesions. Change from Baseline was calculated as the values at Weeks 1, 2, 4, 8, and 12 minus the value at Baseline (Week 0). (NCT00807014)
Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 8, and 12

,
Interventionlesions (Mean)
Non-inflammatory Lesions, Week 1Non-inflammatory Lesions, Week 2Non-inflammatory Lesions, Week 4Non-inflammatory Lesions, Week 8Non-inflammatory Lesions, Week 12Inflammatory Lesions, Week 1Inflammatory Lesions, Week 2Inflammatory Lesions, Week 4Inflammatory Lesions, Week 8Inflammatory Lesions, Week 12Total Lesions, Week 1Total Lesions, Week 2Total Lesions, Week 4Total Lesions, Week 8Total Lesions, Week 12
Differin Gel-6.3-8.2-9.1-8.4-12.6-5.4-8.5-9.6-8.7-11.2-11.7-16.8-18.8-17.1-23.8
Duac Gel-8.5-11.8-16.3-18.4-22.6-10.1-13.0-16.6-17.5-18.8-18.6-24.8-32.9-35.9-41.4

[back to top]

Mean Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Tolerance Symptoms of Itching and Burning

Tolerance symptoms of itching and burning were evaluated at each visit by participants. Possible scores were: 0=absent, 1=mild intermittent, 2=mild persistent, 3=moderate intermittent, 4=moderate persistent, 5=severe intermittent, and 6=severe persistent. (NCT00807014)
Timeframe: Baseline (Week 0); Weeks 1, 2, 4, 8, and 12

,
Interventionscores on a scale (Mean)
Itching, Week 1Itching, Week 2Itching, Week 4Itching, Week 8Itching, Week 12Burning, Week 1Burning, Week 2Burning, Week 4Burning, Week 8Burning, Week 12
Differin Gel0.90.70.70.60.50.90.60.50.60.5
Duac Gel0.40.20.20.10.10.30.10.10.10.0

[back to top]

Mean Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Tolerance Symptoms of Peeling, Erythema, and Dryness

Tolerance symptoms of peeling (flaking), erythema (redness of skin), and dryness were evaluated at each visit by the investigator. Possible scores were: 0=absent, 1=mild intermittent, 2=mild persistent, 3=moderate intermittent, 4=moderate persistent, 5=severe intermittent, and 6=severe persistent. (NCT00807014)
Timeframe: Baseline (Week 0); Weeks 1, 2, 4, 8, and 12

,
Interventionscores on a scale (Mean)
Peeling, Week 1Peeling, Week 2Peeling, Week 4Peeling, Week 8Peeling, Week 12Erythema, Week 1Erythema, Week 2Erythema, Week 4Erythema, Week 8Erythema, Week 12Dryness, Week 1Dryness, Week 2Dryness, Week 4Dryness, Week 8Dryness, Week 12
Differin Gel0.80.60.60.50.40.80.90.70.60.40.80.80.70.60.4
Duac Gel0.50.20.30.10.10.60.30.30.30.20.60.40.30.20.1

[back to top]

Median Percent Change From Baseline in the Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12

Median percent change from baseline in the non-inflammatory lesion counts (open and closed comedones) at Week 12. Comedones are small bumps on the skin (lesions) caused by acne and found at the opening of a skin pore. Open comedones (also known as blackheads) have a microscopic opening to the skin surface, while closed comedones (also known as whiteheads or pimples) lack the opening to the skin. A negative number change from baseline indicates a reduction in lesion counts(improvement). (NCT00829049)
Timeframe: Baseline, Week 12

InterventionPercent Change (Median)
Tazarotene Cream 0.1%-68.14
Adapalene Gel 0.3%-60.00

[back to top]

Median Percent Change From Baseline in Inflammatory Lesion Counts (Papules/Pustules, Nodules) at Week 16

Median percent change from baseline in inflammatory lesion counts (papules/pustules, nodules) at Week 16. Papules and nodules are round, solid elevations of the skin with no visible fluid; papules are smaller (less than 5 to 10 millimeters in width and depth) and nodules are larger (greater than 5 to 10 millimeters in width and depth). Pustules are small elevations of the skin containing cloudy material. A negative number change from baseline indicates a reduction in lesion counts (improvement). (NCT00829049)
Timeframe: Baseline, Week 16

InterventionPercent Change (Median)
Tazarotene Cream 0.1%-67.86
Adapalene Gel 0.3%-55.56

[back to top]

Percentage of Patients With >= 2 Grade Improvement in the Overall Disease Severity Score at Week 12

Percentage of patients with >= 2 grade improvement (decrease in score) in the overall disease severity score at Week 12. The overall disease severity score was evaluated by the investigator using a 7-point scale to rate the overall acne severity (lesions, inflammation, facial redness, and skin condition), where 0=no acne lesions and 6=most severe acne. (NCT00829049)
Timeframe: Week 12

InterventionPercentage of patients (Number)
Tazarotene Cream 0.1%50.8
Adapalene Gel 0.3%32.9

[back to top]

Percentage of Patients With >= 1 Grade Improvement in the Investigator Global Assessment at Week 16

Percentage of patients with >= 1 grade improvement (decrease in score) in the Investigator Global Assessment (IGA) at Week 16. The IGA is a 5-point scale used by the investigator to assess overall acne severity, where 0 equals clear skin (no evidence of acne) and 4 equals severe acne. (NCT00829049)
Timeframe: Week 16

InterventionPercentage of patients (Number)
Tazarotene Cream 0.1%77.0
Adapalene Gel 0.3%66.7

[back to top]

Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline.

Total Sum Score (TSS) is the sum of the 4 local tolerability scores for dryness, erythema, scaling and stinging/burning evaluated at each visit [None=0, Mild=1, Moderate=2 and Severe=3]. In consequence, it ranges from 0 [better outcome] to 12 [worse outcome]and was calculated for each study visit. (NCT00883233)
Timeframe: Week 4

InterventionScores on a scale (Mean)
Adapalene-BPO Gel 3h4.23
Adapalene-BPO Gel EoD3.06
Adapalene-BPO Gel Cetaphil3.25
Adapalene-BPO Gel StD4.13

[back to top]

Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel1.83

[back to top]

Irritant/Allergic Contact Dermatitis

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense." (NCT00887484)
Timeframe: Weeks 1 and 2

,
Interventionunits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel0.040.04
Epiduo Gel0.040.04

[back to top]

Investigators Static Global Assessment

ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions. (NCT00887484)
Timeframe: Baseline, Weeks 5, 8

Interventionunits on a scale (Mean)
BaselineWeek 5Week 8
Clindoxyl Gel2.771.891.62

[back to top]

Inflammatory Acne Lesion Counts

Total number of inflammatory acne lesions (pustules, papules) at each timepoint. (NCT00887484)
Timeframe: Baseline, Weeks 5 and 8

InterventionAcne Lesions (Mean)
BaselineWeek 5Week 8
Clindoxyl Gel14.234.604.26

[back to top]

Erythema (Redness)

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense." (NCT00887484)
Timeframe: Weeks 5 and 8

Interventionunits on a scale (Mean)
Week 5Week 8
Clindoxyl Gel0.220.19

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel0.45

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel0.77

[back to top]

Erythema (Redness)

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense." (NCT00887484)
Timeframe: Weeks 1 and 2

,
Interventionunits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel0.660.55
Epiduo Gel0.910.74

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel0.26

[back to top]

Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel1.911.85
Epiduo Gel1.911.85

[back to top]

Skin Peeling

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense." (NCT00887484)
Timeframe: Weeks 5 and 8

Interventionunits on a scale (Mean)
Week 5Week 8
Clindoxyl Gel0.130.06

[back to top]

Skin Dryness

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense." (NCT00887484)
Timeframe: Weeks 5 and 8

Interventionunits on a scale (Mean)
Week 5Week 8
Clindoxyl Gel0.200.04

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel0.64

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel0.36

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel1.69

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel1.26

[back to top]

Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel1.53

[back to top]

Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel1.63

[back to top]

Total Acne Lesion Counts

Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads), (NCT00887484)
Timeframe: Baseline, Weeks 5 and 8

InterventionAcne Lesions (Mean)
BaselineWeek 5Week 8
Clindoxyl Gel39.0615.9613.77

[back to top]

Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) * 100/28. (NCT00887484)
Timeframe: Baseline, Weeks 2 and 8

InterventionUnits on a scale (Mean)
BaselineWeek 2Week 8
Clindoxyl Gel20.9121.5813.75

[back to top]

Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product? (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionParticipants (Number)
Week 1 - YesWeek 1 - NoWeek 2 - YesWeek 2 - No
Clindoxyl Gel443397
Epiduo Gel26213214

[back to top]

Skin Peeling

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense." (NCT00887484)
Timeframe: Weeks 1 and 2

,
Interventionunits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel0.340.40
Epiduo0.680.60

[back to top]

Skin Dryness

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense." (NCT00887484)
Timeframe: Weeks 1 and 2

,
Interventionunits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel0.470.40
Epiduo Gel0.960.64

[back to top]

Quality of Life Questionnaire - Global Score

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) * 100/116. (NCT00887484)
Timeframe: Baseline, Weeks 2 and 8

InterventionUnits on a scale (Mean)
BaselineWeek 2Week 8
Clindoxyl Gel8.596.305.19

[back to top]

Quality of Life Questionnaire - Functional Domain

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) * 100/48. (NCT00887484)
Timeframe: Baseline, Weeks 2 and 8

InterventionUnits on a scale (Mean)
BaselineWeek 2Week 8
Clindoxyl Gel8.596.305.19

[back to top]

Quality of Life Questionnaire - Emotional Domain

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) * 100/40. (NCT00887484)
Timeframe: Baseline, Weeks 2 and 8

InterventionUnits on a scale (Mean)
BaselineWeek 2Week 8
Clindoxyl Gel25.3219.3816.42

[back to top]

Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally. (NCT00887484)
Timeframe: Weeks 1 and 2

InterventionParticipants (Number)
Week 1, Epiduo Gel, n=47Week 1, Clindoxyl Gel, n=47Week 1, Both Treatments Equally, n=47Week 2, Epiduo Gel, n=46Week 2, Clindoxyl Gel, n=46Week 2, Both Treatments Equally, n=46
All Subjects1530216291

[back to top]

Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product? (NCT00887484)
Timeframe: Week 8

InterventionParticipants (Number)
YesNo
Clindoxyl Gel415

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel0.790.59
Epiduo Gel1.431.04

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel1.090.72
Epiduo Gel1.721.15

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel0.640.72
Epiduo Gel1.020.93

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel1.301.00
Epiduo Gel1.811.41

[back to top]

Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied. (NCT00887484)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Clindoxyl Gel1.61

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel0.910.72
Epiduo Gel1.681.30

[back to top]

Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel2.091.76
Epiduo Gel2.231.98

[back to top]

Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product? (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionParticipants (Number)
Week 1 - YesWeek 1 - NoWeek 2 - YesWeek 2 - No
Clindoxyl Gel16311432
Epiduo Gel12351135

[back to top]

Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product? (NCT00887484)
Timeframe: Week 8

InterventionParticipants (Number)
YesNo
Clindoxyl Gel2818

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel2.231.75
Epiduo Gel2.311.75

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel1.301.35
Epiduo Gel1.321.39

[back to top]

Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel1.871.85
Epiduo Gel2.042.00

[back to top]

Product Acceptability and Preference Questionnaire - Compliance at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale. (NCT00887484)
Timeframe: Week 8

InterventionParticipants (Number)
YesNo
Clindoxyl Gel433

[back to top]

Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable. (NCT00887484)
Timeframe: Weeks 1 and 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Clindoxyl Gel2.812.39
Epiduo Gel3.152.67

[back to top]

Non-inflammatory Acne Lesion Counts

Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint. (NCT00887484)
Timeframe: Baseline, Weeks 5 and 8

InterventionAcne Lesions (Mean)
BaselineWeek 5Week 8
Clindoxyl Gel24.8311.369.51

[back to top]

Irritant/Allergic Contact Dermatitis

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.~Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense." (NCT00887484)
Timeframe: Weeks 5 and 8

Interventionunits on a scale (Mean)
Week 5Week 8
Clindoxyl Gel0.000.00

[back to top]

Change From Baseline in Quantitative Bacteriology Measurements at Week 4

Mean log10 values of P. acnes from swabbed skin samples Please note: Quantitative bacteriologic cultures were obtained from the facial skin (forehead) at screening, baseline, week 2 and week 4/early termination. Samples were obtained according to a modification of the technique of Williamson and Kligman. CFUs of P. acnes were counted at the dilution that contained between 10 and 100 CFUs. Total densities of P. acnes were calculated and reported as the average (of both plates) of the log10 CFUs per cm². (NCT00907101)
Timeframe: Week 4

Interventionlog10 CFU/cm2 (Mean)
Epiduo® Gel-1.6

[back to top]

Worst Post Baseline Tolerability Assessment - Dryness

Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs. (NCT00907101)
Timeframe: Week 4

Interventionparticipants (Number)
NoneMild
Epiduo® Gel264

[back to top]

Worst Post Baseline Tolerability Assessment - Erythema

Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs. (NCT00907101)
Timeframe: Week 4

Interventionparticipants (Number)
NoneMild
Epiduo® Gel300

[back to top]

Worst Post Baseline Tolerability Assessment - Scaling

Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs. (NCT00907101)
Timeframe: Week 4

Interventionparticipants (Number)
NoneMild
Epiduo® Gel291

[back to top]

Worst Post Baseline Tolerability Assessment - Stinging/Burning

Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs. (NCT00907101)
Timeframe: Week 4

Interventionparticipants (Number)
NoneMild
Epiduo® Gel291

[back to top]

Comparative Assessment of Facial Irritation and Cutaneous Effects.

Expert Grader Assessment, including cumulative scores for Erythema and Dryness on a scale of 0=none to 8=severe (NCT00919191)
Timeframe: Daily, for 3 weeks

,
InterventionScores on a Scale (Mean)
Cumulative ErythemaCumulative Dryness
Adapalene Benzoyl Peroxide Facial Gel2.76.2
Tretinoin Facial Gel1.13.2

[back to top]

Self Assessment of Burning/Stinging and Itching

Cumulative scores of Subjects' self assessment of burning/stinging and itching on a score from 0=none to 3=severe (NCT00919191)
Timeframe: Daily, for 3 weeks

,
InterventionScores on a Scale (Mean)
Cumulative Burning/StingingCumulative Itching
Adapalene Benzoyl Peroxide Facial Gel3.71.9
Tretinoin Facial Gel1.40.7

[back to top]

Skin Dryness

"The amount of dryness on the left and right cheek of each panelist.~The scale used to evaluate skin dryness is:~Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring~Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.120.410.320.460.610.690.600.730.560.800.79
Epiduo0.070.250.340.551.731.851.872.291.491.261.33

[back to top]

Self Assessment of Texture (Roughness)

"The amount of roughness on the left and right cheek of each panelist.~The scale used to evaluate roughness is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.280.200.160.320.280.330.250.290.290.330.29
Epiduo0.150.070.070.070.330.190.30.150.150.120.15

[back to top]

Self Assessment of Stinging

"The amount of stinging on the left and right cheek of each panelist.~The scale used to evaluate stinging is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of stinging were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.000.080.080.120.10.170.170.130.130.130.08
Epiduo0.000.000.000.040.40.300.350.150.120.190.12

[back to top]

Self Assessment of Pain

"The amount of pain on the left and right cheek of each panelist.~The scale used to evaluate pain is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.000.040.040.040.040.040.040.040.040.040.04
Epiduo0.000.040.000.000.10.040.040.000.000.000.00

[back to top]

Self Assessment of Oiliness

"The amount of oiliness on the left and right cheek of each panelist.~The scale used to evaluate oiliness is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.120.080.000.080.040.000.000.000.000.000.00
Epiduo0.190.110.040.110.040.070.040.080.00.120.08

[back to top]

Self Assessment of Dryness

"The amount of dryness on the left and right cheek of each panelist.~The scale used to evaluate dryness is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.240.20.160.240.480.540.540.540.500.500.46
Epiduo0.300.190.150.20.670.700.810.850.690.730.69

[back to top]

Self Assessment of Crusting

"The amount of crusting on the left and right cheek of each panelist.~The scale used to evaluate crusting is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.000.000.000.000.000.000.000.000.000.000.00
Epiduo0.000.000.000.000.070.040.040.040.040.000.00

[back to top]

Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?

"The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?~The subject replied using the following scale:~1 - Yes 0 - No" (NCT00926367)
Timeframe: Day 14

Interventionunits on a scale (Mean)
Duac0.58
Epiduo0.54

[back to top]

Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?

"The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How compliant were you with applying the study product each and every day?~The subject replied using the following scale:~0 - Not Compliant at all (<50%)~- Mostly Compliant (50%-79%)~- Very Compliant (80%-100%)" (NCT00926367)
Timeframe: Day 14

Interventionunits on a scale (Mean)
Duac2.00
Epiduo2.00

[back to top]

Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?

"The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How do you rate the comfort of the skin where you are currently treating with the study product?~The subject replied using the following scale:~- Very Comfortable~- Comfortable~- Somewhat Comfortable~- Somewhat Uncomfortable~- Uncomfortable" (NCT00926367)
Timeframe: Day 14

Interventionunits on a scale (Mean)
Duac2.38
Epiduo2.23

[back to top]

Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?

"The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up?~The subject replied using the following scale:~0 - Not Applicable~- Very Easy~- Easy~- Neutral~- Difficult~- Very Difficult" (NCT00926367)
Timeframe: Day 14

Interventionunits on a scale (Mean)
Duac1.17
Epiduo1.00

[back to top]

Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?

"The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up?~The subject replied using the following scale:~0 - Not Applicable~- Very Easy~- Easy~- Neutral~- Difficult~- Very Difficult" (NCT00926367)
Timeframe: Day 14

Interventionunits on a scale (Mean)
Duac1.04
Epiduo1.46

[back to top]

Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?

"The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: What was your overall satisfaction of the study product?~The subject replied using the following scale:~- Very Satisfied~- Satisfied~- Neutral~- Unsatisfied~- Very Unsatisfied" (NCT00926367)
Timeframe: Day 14

Interventionunits on a scale (Mean)
Duac2.29
Epiduo2.46

[back to top]

Self Assessment of Blistering

"The amount of blistering on the left and right cheek of each panelist.~The scale used to evaluate blistering is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.000.000.000.000.000.000.000.000.000.000.00
Epiduo0.000.000.000.000.070.040.000.000.000.000.00

[back to top]

Self Assessment of Burning

"The amount of burning on the left and right cheek of each panelist.~The scale used to evaluate burning is:~Scale Description:~(scale: 0 = none to 3 = severe)~Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14." (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
Interventionunits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac0.000.040.040.120.120.170.170.130.130.080.08
Epiduo0.000.040.040.150.560.700.500.270.310.350.19

[back to top]

Skin Erythema (Redness)

"Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below.~Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion" (NCT00926367)
Timeframe: Baseline, Day 1 through Day 14

,
InterventionUnits on a scale (Mean)
BaselineDay 1Day 2Day 3Day 6Day 7Day 8Day 9Day 10Day 13Day 14
Duac1.562.622.903.083.173.072.872.782.892.852.73
Epiduo1.892.652.522.813.133.082.983.032.942.832.56

[back to top]

Skin Moisture and Hydration

"To assess skin moisture and hydration using transepidermal water loss (TEWL). Results are measured on a continuous scale. Higher values indicate greater water loss/ lower skin moisture levels.~Evaporative water loss measurements provide an instrumental assessment of skin barrier function(one of the layers of the skin. Damage leads to a disruption of the barrier that is accompanied by elevated water loss rates and affects skin moisture and hydration. Higher values indicate greater water loss." (NCT00926367)
Timeframe: Baseline, Days 3, 7, and 14

,
InterventionTEWL rates (gm/m2/hr) (Mean)
BaselineDay 3Day 7Day 14
Duac11.5011.3814.5113.36
Epiduo13.0715.8521.6519.28

[back to top]

Skin Hydration

"The ability of an alternating current to flow through the stratum corneum is an indirect measure of its water content. The value recorded is expressed in microsiemens. Higher values indicate greater levels of skin hydration.~Test results were compared to measurements from the other side of the face, which was not treated instead of referring to a normal range. A normal range does not exist for this measurement. Instead, the non-treated side of the face was used as a control to determine the normal level of skin hydration." (NCT00926367)
Timeframe: Baseline, 4 hrs. post 1st Treatment, Days 3, 7, and 14

,
InterventionMicrosiemens (Mean)
Baseline4 hrs Post 1st TreatmentDay 3Day 7Day 14
Duac378.06323.47420.97385.91401.98
Epiduo392.09415.90465.25414.77418.51

[back to top]

Facial Irritation and Cutaneous Effects

Scores on a scale were recorded each weekday. The scale for Erythema and Dryness was from 0=none to 8=severe (highest possible score is calculated as 8x5daysx3weeks=120). The scale for Burning/Stinging and Itching was from 0=none to 3=severe (highest possible score was calculated as 3x5daysx3weeks=45). The scores that were accumulated through the study for each treatment were then compared. (NCT00952523)
Timeframe: three weeks

,
InterventionScores on a Scale (Mean)
ErythemaDrynessBurning/StingingItching
Adapalene-Benzoyl Peroxide Facial Gel5.47.85.82.9
Tretinoin Facial Gel1.53.11.91.0

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Dryness

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel1.22

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Itching

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel0.63

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Redness

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel1.00

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Scaling

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel0.78

[back to top]

Erythema (Redness) Score

Investigator assessment of tolerability (erythema) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense. (NCT00964223)
Timeframe: Week 5, Week 8

InterventionUnits on a scale (Mean)
Week 5Week 8
Duac Gel0.260.19

[back to top]

Erythema (Redness) Score

Investigator assessment of tolerability (irritant/allergic contact dermatitis) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel0.270.18
Epiduo Gel0.580.36

[back to top]

Inflammatory Acne Lesion Counts

Total number of inflammatory acne lesions (pustules, papules) at each timepoint. (NCT00964223)
Timeframe: Week 5, Week 8

Interventioninflammatory acne lesions (Mean)
Week 5Week 8
Duac Gel8.447.00

[back to top]

Investigator Static Global Assessment Score

ISGA is evaluated using the following scale: 0, clear, clear skin with no lesions; 1, almost clear, rare non-inflammatory lesions; 2, mild, some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions; 3, moderate, up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, severe, up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, very severe, many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions. (NCT00964223)
Timeframe: Week 5, Week 8

InterventionUnits on a scale (Mean)
Week 5Week 8
Duac Gel2.632.15

[back to top]

Irritant/Allergic Contact Dermatitis Score

"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis) on the face.~Erythema,peeling, and dryness were graded using the following scale:~0 None~Slight~Moderate~Intense" (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel0.000.00
Epiduo Gel0.150.00

[back to top]

Irritant/Allergic Contact Dermatitis Score

Investigator assessment of tolerability (contact dermatitis) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense. (NCT00964223)
Timeframe: Week 5, Week 8

InterventionUnits on a scale (Mean)
Week 5Week 8
Duac Gel0.040.00

[back to top]

Non-Inflammatory Acne Lesion Counts

Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint. (NCT00964223)
Timeframe: Week 5, Week 8

Interventionnon-inflammatory acne lesions (Mean)
Week 5Week 8
Duac Gel14.3710.81

[back to top]

Product Acceptability and Preference Questionnaire - Comfort of Skin

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very comfortable; 2, comfortable; 3, somewhat comfortable; 4, somewhat uncomfortable; 5, uncomfortable. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel2.382.00
Epiduo Gel2.582.25

[back to top]

Product Acceptability and Preference Questionnaire - Compliance

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, non-compliant (< 50% of the week); 1, mostly compliant (50-79%); 2, very compliant (80-100%). (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel1.961.93
Epiduo Gel1.931.93

[back to top]

Product Acceptability and Preference Questionnaire - Compliance

Subject response to question regarding use of the product every day or not at week 8 time point answering Yes or No (NCT00964223)
Timeframe: Week 8

InterventionParticipants (Number)
YesNo
Duac Gel243

[back to top]

Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, highly favorable; 2, favorable; 3, neutral; 4, unfavorable; 5, highly unfavorable. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel2.272.14
Epiduo Gel2.272.07

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Application of Product

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very easy; 2, easy; 3, neutral; 4, difficult; 5, very difficult. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel1.461.43
Epiduo Gel1.501.50

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, not applicable; 1, very easy; 2, easy; 3, neutral; 4, difficult. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel2.311.59
Epiduo Gel2.381.59

[back to top]

Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin

Subject response to question: did you feel that your skin was hydrated and moisturized while you on your study product? (Yes or No). (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionParticipants (Number)
Week 1 - YesWeek 1 - NoWeek 2 - YesWeek 2 - No
Duac Gel188198
Epiduo Gel1610189

[back to top]

Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin

Subject response to question: did you feel that your skin was hydrated and moisturized while you on your study product? (Yes or No). (NCT00964223)
Timeframe: Week 8

InterventionParticipants (Number)
YesNo
Duac Gel243

[back to top]

Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 1, very satisfied; 2, satisfied; 3, neutral; 4, unsatisfied; 5, very unsatisfied. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel2.042.21
Epiduo Gel2.192.32

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Burning

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel1.120.73
Epiduo Gel1.961.11

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Dryness

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel1.421.31
Epiduo Gel1.881.58

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Itching

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel1.190.81
Epiduo Gel1.421.19

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Redness

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel1.120.78
Epiduo Gel1.541.00

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Scaling

Product Acceptability and Preference Questionnaire was completed by the subject at weeks 1 and 2 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel0.770.69
Epiduo Gel1.151.00

[back to top]

Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment

Subject response to the following question: If you were to choose to continue treatment for your acne, which treatment would you choose? (Yes or No). (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionParticipants (Number)
Week 1 - YesWeek 1 - NoWeek 2 - YesWeek 2 - No
Duac Gel1951610
Epiduo Gel1510189

[back to top]

Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment

Subject response to the following question: If you were to choose to continue treatment for your acne, which treatment would you choose? (Yes or No). (NCT00964223)
Timeframe: Week 8

InterventionParticipants (Number)
YesNo
Duac Gel207

[back to top]

Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With?

Product Acceptability and Preference Questionnaire was completed by the subject at week 1 and week 2 asking which study product they were more satisfied with: Duac or Epiduo. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionParticipants (Number)
Week 1Week 2
Duac Gel1712
Epiduo Gel815

[back to top]

Skin Dryness Score

Investigator assessment of tolerability (skin dryness) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense. (NCT00964223)
Timeframe: Week 5, Week 8

InterventionUnits on a scale (Mean)
Week 5Week 8
Duac Gel0.150.00

[back to top]

Skin Peeling Score

Investigator assessment of tolerability (skin peeling) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense. (NCT00964223)
Timeframe: Week 5, Week 8

InterventionUnits on a scale (Mean)
Week 5Week 8
Duac Gel0.000.00

[back to top]

Skin Peeling Score

Investigator assessment of tolerability (skin peeling) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; Intense, 3. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel0.150.18
Epiduo Gel0.540.21

[back to top]

Skindex-29 Quality of Life Questionnaire - Emotional Domain

"Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: never to all the time, higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain." (NCT00964223)
Timeframe: Baseline, and Week 8

InterventionUnits on a scale (Mean)
BaselineWeek 8
Duac Gel44.2935.37

[back to top]

Skindex-29 Quality of Life Questionnaire - Functional Domain

"Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: never to all the time, higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain." (NCT00964223)
Timeframe: Baseline, and Week 8

InterventionUnits on a scale (Mean)
BaselineWeek 8
Duac Gel14.069.10

[back to top]

Skindex-29 Quality of Life Questionnaire - Global Score

"Skindex-29 Quality of Life (QoL)Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: never to all the time, higher scores for each domain indicate worse effects on QoL. The Global Score ranges from 0 to 100. Higher scores indicate worse QoL for that domain." (NCT00964223)
Timeframe: Baseline, and Week 8

InterventionUnits on a scale (Mean)
BaselineWeek 8
Duac Gel14.069.10

[back to top]

Skindex-29 Quality of Life Questionnaire - Symptomatic Domain

"Skindex-29 Quality of Life (QoL) Questionnaire used in dermatological disease consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point scale from: never to all the time, higher scores for each domain indicate worse effects on QoL. Scores range from 0 to 100. Higher scores indicate worse QoL for that domain." (NCT00964223)
Timeframe: Baseline, and Week 8

InterventionUnits on a scale (Mean)
BaselineWeek 8
Duac Gel28.1021.72

[back to top]

Total Acne Lesion Counts

Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads), (NCT00964223)
Timeframe: Week 5, Week 8

Interventiontotal acne lesions (Mean)
Week 5Week 8
Duac Gel22.8117.81

[back to top]

Skin Dryness Score

Investigator assessment of tolerability (skin dryness) on the face. Erythema, peeling, and dryness were graded using the following Investigator Assessment of Tolerability scale: 0, None; 1, Slight; 2, Moderate; 3, Intense. (NCT00964223)
Timeframe: Week 1, Week 2

,
InterventionUnits on a scale (Mean)
Week 1Week 2
Duac Gel0.150.14
Epiduo Gel0.460.29

[back to top]

Product Acceptability and Preference Questionnaire - Comfort of Skin

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very comfortable; 2, comfortable; 3, somewhat comfortable; 4, somewhat uncomfortable; 5, uncomfortable. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel1.78

[back to top]

Product Acceptability and Preference Questionnaire - Comparison of Study Products to Products Used in the Past

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, more satisfied; 2, somewhat more satisfied; 3, neither satisfied or dissatisfied; 4, more satisfied; 5, more dissatisfied. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel1.93

[back to top]

Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, highly favorable; 2, favorable; 3, neutral; 4, unfavorable; 5, highly unfavorable. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel2.07

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Application of Product

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very easy; 2, easy; 3, neutral; 4, difficult; 5, very difficult. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel1.26

[back to top]

Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up

Measure Description Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, not applicable; 1, very easy; 2, easy; 3, neutral; 4, difficult. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel1.89

[back to top]

Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, very satisfied; 2, satisfied; 3, neutral; 4, unsatisfied; 5, very unsatisfied. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel2.52

[back to top]

Product Acceptability and Preference Questionnaire - Severity of Burning

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, none; 1, very minimal; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT00964223)
Timeframe: Week 8

InterventionUnits on a scale (Mean)
Duac Gel0.63

[back to top]

Percent Change From Baseline in Total Lesion Count

Percent change from Baseline in Total Lesion count (sum of Non-Inflammatory and Inflammatory lesions) at Week 12. (NCT01014689)
Timeframe: Baseline and Week 12

Interventionpercent of change (Median)
Adapalene 0.1% / BPO 2.5% Gel + Lymecycline-74.1
Adapalene 0.1% / BPO 2.5% Vehicle Gel + Lymecycline-56.8

[back to top]

Success Rate on the Investigator's Global Assessment (IGA) at Week 12

"Percentage of Subjects Clear or Almost Clear on 6-point IGA scale(0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe and 5=very severe) at Week 12." (NCT01014689)
Timeframe: Baseline and Week 12

Interventionpercent of subjects (Number)
Adapalene 0.1% / BPO 2.5% Gel + Lymecycline47.6
Adapalene 0.1% / BPO 2.5% Vehicle Gel + Lymecycline33.7

[back to top]

Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.

Number of participants who were a success with regard to worst post-baseline tolerability assessment scores in each category of the tolerability assessments from baseline to week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success for each category was defined as a tolerability score of 0. (NCT01046396)
Timeframe: baseline to week 3

,
Interventionparticipants (Number)
ErythemaScalingDrynessStinging / Burning
Differin® Cream 0.1%9321458
Differin® Lotion 0.1%9301456

[back to top]

6 Question Subject Cosmetic Acceptability Questionnaire at Week 3

Number of participants in each category (Differin® Lotion, Differin® Cream or No Preference) of each question of the Subject Cosmetic Acceptability Questionnaire at week 3. (NCT01046396)
Timeframe: week 3

,,
Interventionparticipants (Number)
Which side was easier to apply?Which side absorbed into your skin more quickly?Which side had less odor?Which side felt better on your skin?Which side left less residue on your skin?Generally, which side did you prefer?
Differin® Cream 0.1%19277261823
Differin® Lotion 0.1%121710151513
No Preference332047233128

[back to top]

6 Question Subject Cosmetic Acceptability Questionnaire

Number of participants in each category (Differin® Lotion, Differin® Cream or No Preference) for each question of the Subject Cosmetic Acceptability Questionnaire at week 3. (NCT01046565)
Timeframe: week 3

,,
Interventionparticipants (Number)
Which side was easier to apply?Which side absorbed into your skin more quickly?Which side had less odor?Which side felt better on your skin?Which side left less residue on your skin?Generally, which side did you prefer?
Differin® Cream 0.1%17257271526
Differin® Lotion 0.1%14234222223
No Preference442764263826

[back to top]

Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.

Number of participants who were a success with regard to worst post-baseline tolerability assessment scores in each category of the tolerability assessments from baseline to week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success for each category was defined as a tolerability score of 0. (NCT01046565)
Timeframe: baseline to week 3

,
Interventionparticipants (Number)
ErythemaScalingDrynessStinging/Burning
Differin Cream 0.1%33614460
Differin® Lotion 0.1%35584657

[back to top]

Success Rate

Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA) (NCT01138735)
Timeframe: Baseline to Week 12 (Last Observation Carried Forward [LOCF])

Interventionpercentage of participant (Number)
Adapalene/Benzoyl Peroxide47.2
Topical Gel Vehicle15.4

[back to top]

Change From Baseline in Total Lesion Counts

(NCT01138735)
Timeframe: Baseline to Week 12 (LOCF)

Interventionlesion count change (Mean)
Adapalene/Benzoyl Peroxide-27.6
Topical Gel Vehicle-3.6

[back to top]

Change in Inflammatory Lesion Counts From Baseline

(NCT01138735)
Timeframe: Baseline to Week 12 (LOCF)

Interventionlesion count change (Mean)
Adapalene/Benzoyl Peroxide-7.4
Topical Gel Vehicle-0.7

[back to top]

Percent Change in Total Lesion Counts From Baseline

(NCT01138735)
Timeframe: Baseline to Week 12 (LOCF)

Interventionpercentage of change in lesion count (Mean)
Adapalene/Benzoyl Peroxide-55.5
Topical Gel Vehicle-9.3

[back to top]

Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12

Number of participants who were a Success (Subject's Global Assessment of 'Clear or 'Almost Clear') at week 12. Subject's Global Assessment is measured on a scale (Clear, Almost Clear, Mild, Moderate, Severe, Very Severe) with Clear being best and Very Severe being worst. (NCT01209949)
Timeframe: 12 weeks

Interventionparticipants (Number)
Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel18

[back to top]

Number of Participants With Tolerability Assessments Resulting in an Adverse Event

Number of participants with tolerability assessments resulting in an adverse event. Tolerability assessments include erythema (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Scaling (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Dryness (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Stinging/Burning (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with a score of None being best and a score of Severe being worst. (NCT01209949)
Timeframe: 12 weeks

Interventionparticipants (Number)
Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel2

[back to top]

Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12.

Mean percent change from baseline in lesions counts (inflammatory, non-inflammatory, and total) at week 12. (NCT01209949)
Timeframe: Week 12

Interventionpercent change from baseline (Mean)
Inflammatory LesionsNoninflammatory LesionsTotal Lesions
Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel-44.1-57.1-49.7

[back to top]

Global Scarring Severity

"Grade Level:~Macular disease~Mild disease~Moderate disease~Severe disease" (NCT01213199)
Timeframe: Week 24

Interventionunits on a scale (Mean)
Differin® 0.3% Gel2.7

[back to top]

Change From Baseline in Global Acne Assessment Score (GAAS) at Week 12

GAAS was conducted by the investigator. The patient's facial acne was evaluated on a 5 point scale 0=None (no evidence of acne), 1=Minimal (few lesions), 2=Mild (several to many non-inflammatory lesions; few inflammatory lesions), 3=Moderate (many lesions) to 4=Severe (Significant degree of inflammatory disease; papules/pustules present, few nodulo-cystic lesions; comedones may be present). Papules and nodules are round, solid elevations of the skin with no visible fluid. A negative change from baseline indicates improvement. (NCT01231334)
Timeframe: Baseline, Week 12

,
InterventionScore on a scale (Mean)
BaselineChange from baseline at Week 12
Aczone® Gel 5% Plus Differin® 0.3% Gel2.80-0.87
Duac® Topical Gel Plus Differin® 0.3% Gel2.84-1.27

[back to top]

Percent Change From Baseline in Inflammatory Lesion Counts at Week 12

Percent Change from baseline in inflammatory lesion counts (papules, pustules and nodules) at week 12. Papules and nodules are round, solid elevations of the skin with no visible fluid; papules are smaller (less than 5 or 10 millimeters in width and depth) and nodules are larger (greater than 5 or 10 millimeters in width and depth). Pustules are small elevations of the skin containing cloudy material. A negative number change from baseline indicates a reduction in lesion counts (improvement). (NCT01231334)
Timeframe: Baseline, Week 12

InterventionPercent change (Median)
Aczone® Gel 5% Plus Differin® 0.3% Gel-70.7
Duac® Topical Gel Plus Differin® 0.3% Gel-75.9

[back to top]

Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12

"Percent Change from baseline in non-inflammatory lesion counts (open/closed comedones) at week 12. Comedones are small bumps on the skin (lesions) caused by acne and found at the opening of a skin pore. Open comedones (also known as a blackheads) have a microscopic opening to the skin surface, while closed comedones (also known as whiteheads or pimples) lack the opening to the skin. A negative number change from baseline indicates a reduction in lesion counts (improvement)." (NCT01231334)
Timeframe: Baseline, Week 12

InterventionPercent change (Median)
Aczone® Gel 5% Plus Differin® 0.3% Gel-55.3
Duac® Topical Gel Plus Differin® 0.3% Gel-60.7

[back to top]

Percent Change From Baseline in Total Lesion Count at Week 12

Percent change in total lesion counts: inflammatory (papules, pustules and nodules) and non-inflammatory (comedones) lesion counts from baseline. Papules and nodules are round, solid elevations of the skin with no visible fluid; papules are smaller (less than 5 or 10 millimeters ) and nodules are larger (greater than 5 or 10 millimeters). Pustules are small elevations of the skin containing cloudy material. Comedones are small bumps on the skin caused by acne and found at the opening of a skin pore. A negative change from baseline indicates a reduction in lesion counts (improvement). (NCT01231334)
Timeframe: Baseline, Week 12

InterventionPercent change (Median)
Aczone® Gel 5% Plus Differin® 0.3% Gel-62.7
Duac® Topical Gel Plus Differin® 0.3% Gel-65.0

[back to top]

Percentage of Participants at Week 12 Having at Least a One Point Decrease in Overall Disease Severity

The overall disease severity was evaluated by the investigator at Baseline and Week 12 using a 7-point scale to rate the overall acne severity (lesions, inflammation, facial redness and skin condition), where 0=no acne lesions and 6=most severe acne. The percentage of participants with at least a one point decrease (improvement) from baseline is calculated. (NCT01231334)
Timeframe: Baseline, Week 12

InterventionPercentage of participants (Number)
Aczone® Gel 5% Plus Differin® 0.3% Gel83.5
Duac® Topical Gel Plus Differin® 0.3% Gel92.4

[back to top]

Percentage of Participants Demonstrating a ≥ 1 Category Increase in Tolerability From Baseline at Week 12

The investigator rated the patient's current symptoms of erythema, dryness, peeling, and oiliness on a 5 point scale from 0 (Absent) to 4 (Severe). The investigator rated the symptoms of pruritus and burning since last visit on a 6 point scale of 0 (Absent) to 5 (Severe)-interfering with daily activities. Percentage of participants demonstrating a ≥1 category increase (improvement) in tolerability from baseline is calculated. (NCT01231334)
Timeframe: Baseline, Week 12

,
InterventionPercentage of participants (Number)
DrynessPeelingOilinessErythemaPruritusBurning
Aczone® Gel 5% Plus Differin® 0.3% Gel21.311.56.78.212.413.2
Duac® Topical Gel Plus Differin® 0.3% Gel11.99.36.06.88.512.7

[back to top]

Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12

GAAS was conducted by the investigator at Baseline and Week 12. The patient's facial acne was evaluated on a 5 point scale 0=None (no evidence of acne), 1=Minimal (few lesions), 2=Mild (several to many non-inflammatory lesions; few inflammatory lesions), 3=Moderate (many lesions) to 4=Severe (Significant degree of inflammatory disease; papules/pustules present, few nodulo-cystic lesions; comedones may be present). Papules/nodules are round, solid elevations of the skin with no visible fluid. The percentage of participants with at least a one point decrease (improvement) in GAAS was calculated. (NCT01231334)
Timeframe: Baseline, Week 12

InterventionPercentage of participants (Number)
Aczone® Gel 5% Plus Differin® 0.3% Gel69.7
Duac® Topical Gel Plus Differin® 0.3% Gel81.4

[back to top]

Change in Acne Lesion Count

Change in total count of acne lesions from baseline visit to Week 6 visit (NCT01504204)
Timeframe: Baseline and 6 weeks

,
Interventionlesions (Mean)
Basleine (Inflammatory Lesions)Baseline (Non-Inflammatory)Week 6 (inflammatory Lesion)Week 6 (Non-inflammatory Lesion)
Medication With Sample and Demonstration333119
Medication Without Samples238135

[back to top]

Adherence to Study Medication

Adherence will be reported as percentage of prescribed doses taken as measured electronically by a Medication Event Monitoring System (MEMS®) cap. (NCT01504204)
Timeframe: Baseline to 6 weeks

Interventionpercentage of doses (Median)
Medication With Sample and Demonstration86
Medication Without Samples71

[back to top]

Change in Acne Global Assessment

Change in the physician's global assessment of acne severity on a validated 0-5 scale (0=clear to 5=very severe) from baseline to Week 6 visit. (NCT01504204)
Timeframe: Baseline and 6 weeks

InterventionParticipants (Count of Participants)
Baseline71966884Baseline71966885Week 671966884Week 671966885
AGA (2-mild)AGA (3 moderate)AGA (1 almost clear)
Medication With Sample and Demonstration5
Medication Without Samples6
Medication With Sample and Demonstration4
Medication With Sample and Demonstration0
Medication Without Samples0
Medication With Sample and Demonstration3
Medication Without Samples4
Medication With Sample and Demonstration2
Medication Without Samples3
Medication Without Samples2

[back to top]

Local Tolerability (Stinging/Burning)

Highest Severity of Local Tolerability Scores Worse Than Baseline (NCT01910064)
Timeframe: 12 months

Interventionsubjects (Number)
MildModerateSevere
GK530G251799

[back to top]

Local Tolerability (Dryness)

Highest Severity of Local Tolerability Scores Worse Than Baseline (NCT01910064)
Timeframe: 12 months

Interventionparticipants (Number)
MildModerateSevere
GK530G254521

[back to top]

Local Tolerability (Erythema)

Highest severity of Local tolerability scores worth than base line (NCT01910064)
Timeframe: 12 monhths

Interventionparticipants (Number)
MildModerateSevere
GK530G149645

[back to top]

Local Tolerability (Pruritus)

Highest Severity of Local Tolerability Scores Worse Than Baseline (NCT01910064)
Timeframe: 12 months

Interventionparticipants (Number)
MildModerateSevere
GK530G149354

[back to top]

Local Tolerability (Scaling)

Highest severity of Local tolerability scores worth than base line (NCT01910064)
Timeframe: 12 months

Interventionparticipants (Number)
MildModerateSevere
GK530G191602

[back to top]

Percent Changes From Baseline in Total Lesion Counts

(NCT01910064)
Timeframe: Baseline, Weeks 1, 2, 4, and Months 2, 3, 6, 9, 12

Interventionpercent change (Median)
Week 1Week 2Week 4Month 2Month 3Month 6Month 9Month 12
GK530G25.642.152.967.174.782.083.686.2

[back to top]

Total Lesion Count

The change in total lesion count after use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 2 weeks, 4 weeks, and 8 weeks. (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

Interventionlesions (Mean)
BaselineWeek 2Week 4Week 8
Adapalene/BPO Gel/Foam Wash/Moisturizer76.753.950.043.7

[back to top]

Subject Questionnaire

Describe subject satisfaction after use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 8 weeks. (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

Interventionparticipants (Number)
Very satisfiedSatisfiedUndecidedDissatisfiedVery dissatisfiedMissing
Adapalene/BPO Gel/Foam Wash/Moisturizer23425313

[back to top]

Stinging/Burning

Cutaneous irritability assessments (stinging/burning, erythema, scaling, dryness) experienced during use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 8 weeks. (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

,,,
Interventionparticipants (Number)
NoneMildModerateSevere
Baseline80100
Week 2482350
Week 4631210
Week 8621000

[back to top]

Scaling

Cutaneous irritability assessments (stinging/burning, erythema, scaling, dryness) experienced during use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 8 weeks. (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

,,,
Interventionparticipants (Number)
NoneMildModerateSevere
Baseline73800
Week 2571540
Week 465920
Week 863900

[back to top]

Non-inflammatory Lesions

The change in non-inflammatory lesions after use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 2 weeks, 4 weeks, and 8 weeks (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

Interventionlesions (Mean)
BaselineWeek 2Week 4Week 8
Adapalene/BPO Gel/Foam Wash/Moisturizer49.436.434.129.2

[back to top]

Inflammatory Lesions

The change in inflammatory lesions after use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 2 weeks, 4 weeks, and 8 weeks. (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

Interventionlesions (Mean)
BaselineWeek 2Week 4Week 8
Adapalene/BPO Gel/Foam Wash/Moisturizer27.317.415.714.4

[back to top]

Dryness

Cutaneous irritability assessments (stinging/burning, erythema, scaling, dryness) experienced during use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 8 weeks. (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

,,,
Interventionparticipants (Number)
NoneMildModerateSevere
Baseline711000
Week 2452290
Week 4561910
Week 8601110

[back to top]

Erythema

Cutaneous irritability assessments (stinging/burning, erythema, scaling, dryness) experienced during use of adapalene BPO gel in conjunction with Foam Wash and Moisturizer SPF 30 for 8 weeks. (NCT01951417)
Timeframe: Baseline, 2, 4, and 8 weeks

,,,
Interventionparticipants (Number)
NoneMildModerateSevere
Baseline502830
Week 2492070
Week 4452650
Week 8521820

[back to top]

Local Tolerability (Stinging/Burning)

Highest severity of local tolerability scores worse than Baseline (NCT02073448)
Timeframe: 12 weeks

,,
Interventionparticipants (Number)
MildModerateSevere
CD027149112
CD15792191
GK530G106767

[back to top]

Local Tolerability (Scaling)

Highest severity of local tolerability scores worse than Baseline (NCT02073448)
Timeframe: 12 weeks

,,
Interventionparticipants (Number)
MildModerateSevere
CD02713791
CD15792430
GK530G105331

[back to top]

Percent Changes From Baseline in Total Lesion Counts

(NCT02073448)
Timeframe: Baseline - Week12

Interventionpercent change (Median)
CD027168.6
GK530G82.7
CD157981.6

[back to top]

Percent of Subjects With Adverse Events

(NCT02073448)
Timeframe: up to 12 weeks

Interventionpercentage of participants (Number)
CD027127.7
GK530G44.8
CD157937.5

[back to top]

Local Tolerability (Dryness)

Highest severity of local tolerability scores worse than Baseline (NCT02073448)
Timeframe: 12 weeks

,,
Interventionparticipants (Number)
MildModerateSevere
CD02714461
CD15792940
GK530G113311

[back to top]

Local Tolerability (Erythema)

Highest severity of local tolerability scores worse than Baseline (NCT02073448)
Timeframe: 12 weeks

,,
Interventionparticipants (Number)
MildModerateSevere
CD02713250
CD15792041
GK530G78242

[back to top]

Local Tolerability (Pruritus)

Highest severity of local tolerability scores worse than Baseline (NCT02073448)
Timeframe: 12 weeks

,,
Interventionparticipants (Number)
MildModerateSevere
CD02712420
CD15792491
GK530G61213

[back to top]

Skin Tolerability: Skin Sebum Content and Skin Hydration

Skin tolerability was assessed by measuring the skin surface sebum content, skin hydration with the Sebumeter SM815 and Corneometer CM825, respectively (NCT02173054)
Timeframe: Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.

,,
Interventionµg/cm^2 (Mean)
Baseline SebumeterWeek 8 SebumeterBaseline CorneometerWeek 8 Corneometer
Adapalene Gel75.763.651.750.9
Adapalene Gel With Eucerin73.764.246.748.6
Adapalene Gel With Placebo Moisturizer71.259.950.249.5

[back to top]

Skin Tolerability: Transepidermal Water Loss (TEWL)

Skin tolerability was assessed by measuring TEWL with the Tewameter TM300 (NCT02173054)
Timeframe: Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.

,,
Interventiong/m^2h (Mean)
Baseline TEWLWeek 8 TEWL
Adapalene Gel9.812.3
Adapalene Gel With Eucerin10.611.5
Adapalene Gel With Placebo Moisturizer10.411.8

[back to top]

Reduction of Severity of Acne: Acne Severity Index (ASI)

"The ASI score was calculated from the number of papules + (2 x pustules) + (comedones/4)~Decrease of ASI score are considered to be a better outcome" (NCT02173054)
Timeframe: baseline, 2nd week, 4th week and 8th week

,,
Interventionunits on a scale (Mean)
Baseline ASIWeek 2 ASIWeek 4 ASIWeek 8 ASI
Adapalene Gel11.714.413.69.5
Adapalene Gel With Eucerin9.58.79.27.1
Adapalene Gel With Placebo Moisturizer9.410.49.29.3

[back to top]

Reduction of Severity of Acne

"Evaluation from mean counts of inflammatory, noninflammatory, and total acne lesions at baseline, and at 2, 4, and 8 weeks~Total acne lesions = inflammatory + noninflammatory acne lesions~Reduction of lesions counts are considered to be a better outcome" (NCT02173054)
Timeframe: baseline, 2nd week, 4th week and 8th week

,,
InterventionLesions (Mean)
Baseline Total Lesion CountWeek 2 Total Lesion CountWeek 4 Total Lesion CountWeek 8 Total Lesion CountBaseline Inflammatory Lesion CountsWeek 2 Inflammatory Lesion CountsWeek 4 Inflammatory Lesion CountsWeek 8 Inflammatory Lesion CountsBaseline Noninflammatory CountsWeek 2 Noninflammatory CountsWeek 4 Noninflammatory CountsWeek 8 Noninflammatory Counts
Adapalene Gel35.9413928.93.54.53.62.532.436.535.426.4
Adapalene Gel With Eucerin25.523.825.719.93.83.63.42.421.620.522.617.7
Adapalene Gel With Placebo Moisturizer27.426.627.326.834.12.93.124.522.524.423.7

[back to top]

Reduction of Undesirable Effects

"Undesirable effects were evaluated from skin's condition/signs(erythema, dryness and scaling) are evaluated by dermatologist. (none; mild; moderate; severe) and subject interview/symptoms(stinging/burning and pruritis) are evaluated by participants.(none; mild; moderate; severe). There were assessed at 2nd week, 4th week, and 8th week.~The worst score of each parameter which was defined as the worst local tolerance score is demonstrated and compared among 3 groups as shown." (NCT02173054)
Timeframe: 2nd week, 4th week, and 8th week

,,
Interventionparticipants (Number)
Erythema (none)Erythema (mild)Erythema (moderate)Dryness (none)Dryness (mild)Dryness (moderate)Scaling (none)Scaling (mild)Scaling (moderate)Stinging (none)Stinging (mild)Stinging (moderate)Stinging (severe)Pruritus (none)Pruritus (mild)Pruritus (moderate)Pruritus (severe)
Adapalene Gel261032114413224614109181074
Adapalene Gel With Eucerin354032612414161113923952
Adapalene Gel With Placebo Moisturizer3820291101624091213621865

[back to top]

Percent Change From Baseline in Non-inflammatory Lesion Count

(NCT02249104)
Timeframe: Baseline and 8 weeks

InterventionPercent change (Mean)
Acne Treatment-27.1

[back to top]

Percent Change From Baseline in Inflammatory Lesion Count

(NCT02249104)
Timeframe: Baseline and 8 weeks

InterventionPercent change (Mean)
Acne Treatment-35.7

[back to top]

Mean Change From Baseline in Total Lesion Count

(NCT02249104)
Timeframe: Baseline and 8 weeks

InterventionLesions counted (Mean)
Acne Treatment-26.9

[back to top]

Mean Change From Baseline in Non-inflammatory Lesion Count

(NCT02249104)
Timeframe: Baseline and 8 weeks

InterventionLesions counted (Mean)
Acne Treatment-16.3

[back to top]

Mean Change From Baseline in Inflammatory Lesion Count

(NCT02249104)
Timeframe: Baseline and 8 weeks

InterventionLesions counted (Mean)
Acne Treatment-10.8

[back to top]

Percent Change From Baseline in Total Lesion Count

(NCT02249104)
Timeframe: Baseline and 8 weeks

InterventionPercent change (Mean)
Acne Treatment-29.6

[back to top]

Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions

(NCT02525549)
Timeframe: 84 days

Interventionpercent change of lesion counts (Mean)
Test Product54.33
Reference Product55.06
Placebo Product36.40

[back to top]

Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions

(NCT02525549)
Timeframe: 84 days

Interventionpercent change of lesion counts (Mean)
Test Product61.07
Reference Product65.58
Placebo Product41.63

[back to top]

"Percentage of Patients With a Clinical Response of Clinical Success Using the Investigator's Global Assessment (IGA) at Week 12"

"The Investigator's Global Assessment had to show a score of 0 (clear) or 1 (almost clear) to be considered a Clinical Success.~0= Clear skin with no inflammatory or non inflammatory lesions.~Almost clear, rare non-inflammatory lesions with no more than one small inflammatory lesion.~Mild severity; greater than Grade 1; some non inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions).~Moderate severity; greater than Grade 2; up to many non inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion.~Severe; greater than Grade 3, up to many non inflammatory lesions and may have some inflammatory lesions, but no more than a few nodular lesions.~Very severe, greater than Grade 4" (NCT02651220)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w112
Epiduo® Forte Gel 0.3%/2.5% w/w106
Vehicle Topical Gel15

[back to top]

Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions.

(NCT02651220)
Timeframe: 12 weeks

Interventionpercentage of change from baseline (Mean)
Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w-65.4
Epiduo® Forte Gel 0.3%/2.5% w/w-64.5
Vehicle Topical Gel-25.5

[back to top]

Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions.

(NCT02651220)
Timeframe: 12 weeks

Interventionpercentage of change from baseline (Mean)
Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w-74.2
Epiduo® Forte Gel 0.3%/2.5% w/w-73.0
Vehicle Topical Gel-30.6

[back to top]

Percent Change From Baseline in Total Lesions at Week 12

"Percent change from baseline in total lesions at week 12 was assessed by investigator or designee. Investigator or designee counted and recorded the number of open comedones, closed comedones, papules, and pustules on each subject's face. Lesions were counted globally on the following facial locations/quadrants: forehead, left cheek, chin, and right cheek. Each of the following lesion types were analyzed separately for forehead, left cheek, chin, right cheek, and the total of the 4 areas:~Inflammatory acne lesions (sum of papules and pustules)~Non-inflammatory acne lesions (sum of open comedones and closed comedones)~Total lesion counts (sum of inflammatory and non-inflammatory acne lesions counts)" (NCT02755545)
Timeframe: Baseline and 12 weeks

,
InterventionPercent change in lesions (Mean)
Open comedonesClosed comedonesPapulesPustulesInflammatory acne lesionsNon-inflammatory acne lesionsTotal lesion counts
Adapalene-17.1-13.0-4.2-30.1-10.0-34.7-28.3
Salicylic Acid-45.67.66.4-18.21.1-22.8-17.5

[back to top]

Percent Change From Baseline in Total Lesion Count

Percent Change From Baseline in Total Lesion Count. (NCT02899000)
Timeframe: Weeks 4, 8, and 12

Interventionpercent change in lesions (Mean)
Week 4Week 8Week 12
Acne Treatment-38.9-53.9-62.6

[back to top]

Number and Percent of Adverse Events

Number and percent of subjects with any Treatment-Related Adverse Event (NCT02899000)
Timeframe: Week 12

InterventionParticipants (Count of Participants)
Acne Treatment27

[back to top]

Change in Number of Inflammatory Lesions

Change in Number of Inflammatory Lesions from baseline. (NCT02899000)
Timeframe: Week 12

InterventionInflammatory lesions (Mean)
Acne Treatment-30.1

[back to top]

Subject Assessment of Acne Improvement

Subject Assessment of Acne Improvement on a 6 point scale (0 = Complete Improvement, 1 = Marked Improvement, 2 = Moderate Improvement, 3 = Minimal Improvement, 4 = No Change, 5 = Worse). (NCT02899000)
Timeframe: Week 12

Interventionscore on a scale (Mean)
Acne Treatment1.3

[back to top]

Change From Baseline in Inflammatory Lesion Count

Change From Baseline in Inflammatory Lesion Count. (NCT02899000)
Timeframe: Weeks 4, 8, and 12

Interventionchange in lesions (Mean)
Week 4Week 8Week 12
Acne Treatment-18.9-25.9-30.1

[back to top]

Change From Baseline in Non-Inflammatory Lesion Count

Change From Baseline in Non-Inflammatory Lesion Count. (NCT02899000)
Timeframe: Weeks 4, 8, and 12

Interventionchange in lesions (Mean)
Week 4Week 8Week 12
Acne Treatment-24.9-33.6-39.1

[back to top]

Change From Baseline in Total Lesion Count

Change From Baseline in Total Lesion Count. (NCT02899000)
Timeframe: Weeks 4, 8, and 12

Interventionchange in lesions (Mean)
Week 4Week 8Week 12
Acne Treatment-43.7-59.4-69.2

[back to top]

Investigator's Evaluation: Number of Subjects Not Considered to be Oral Isotretinoin Candidates

"At each visit, subjects were evaluated by the investigator to determine whether (in the opinion of the investigator) they would consider them as candidates for oral isotretinoin therapy.~The outcome measure reports the number and % of subjects who, in the opinion of the investigator, were not considered to be a candidate for oral isotretinoin therapy." (NCT02899000)
Timeframe: Weeks 0, 4, 8, and 12

InterventionParticipants (Count of Participants)
Week 0Week 4Week 8Week 12
Acne Treatment078121149

[back to top]

Number and Percent of Subjects With IGA Success

IGA Success is defined as an IGA rating of Clear (Grade 0) or Almost Clear (Grade 1) (NCT02899000)
Timeframe: Weeks 4, 8, and 12

InterventionParticipants (Count of Participants)
Week 4Week 8Week 12
Acne Treatment94469

[back to top]

Percent Change From Baseline in Inflammatory Lesion Count

Percent Change From Baseline in Inflammatory Lesion Count. (NCT02899000)
Timeframe: Weeks 4, 8, and 12

Interventionpercent change in lesions (Mean)
Week 4Week 8Week 12
Acne Treatment-38.5-55.0-66.2

[back to top]

Percent Change From Baseline in Non-Inflammatory Lesion Count

Percent Change From Baseline in Non-Inflammatory Lesion Count. (NCT02899000)
Timeframe: Weeks 4, 8, and 12

Interventionpercent change in lesions (Mean)
Week 4Week 8Week 12
Acne Treatment-34.6-50.2-58.7

[back to top]

Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire

% of subjects satisfied to very satisfied with study treatment at week 12 (NCT02932267)
Timeframe: At week 12

InterventionParticipants (Count of Participants)
Adapalene / BPO Gel36

[back to top]

Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count

Per protocol population (NCT03393494)
Timeframe: Day 1 to week 12

Interventionpercentage of lesion change (Mean)
Perrigo Active62.75
Reference Active60.78
Perrigo Placebo43.45

[back to top]

Mean Percent Change From Baseline in the Papules and Pustules Lesion Count

(NCT03393494)
Timeframe: Day 1 to week 12

Interventionpercentage of lesion change (Mean)
Perrigo Active68.18
Reference Active63.56
Perrigo Placebo50.72

[back to top]

IGA Score

The percent of subjects who have at least a 2 grade improvement on IGA score (NCT03457636)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide19

[back to top]

Investigator Global Assessment (IGA) Score

The IGA is an assessment by the Investigator to assess the severity of the subject's disease wherein 0=Clear Skin, 1=Almost Clear, 2=Mild Severity, 3=Moderate, 4=Severe, 5=Very Severe. Lower score indicate less severe disease. (NCT03457636)
Timeframe: Baseline, Week 4, Week 8, Week 12

InterventionParticipants (Count of Participants)
Baseline72475436Week 472475436Week 872475436Week 1272475436
Almost ClearClearSevereModerateMild
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide20
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide0
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide5
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide15
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide2
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide10
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide8
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide6
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide1
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide13

[back to top]

Non-inflammatory Lesion Count

Non-inflammatory lesions here include open and closed comedones. These are counted on the face by the investigator from edge of hairline to mandibular line and lower count indicates less severe disease. (NCT03457636)
Timeframe: Baseline, Week 4, Week 8, Week 12

Interventionlesion count (Median)
BaselineWeek 4Week 8Week 12
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide3327179

[back to top]

Inflammatory Lesion Count

Inflammatory lesions here include papules and pustules on the face from edge of hairline to mandibular line as counted by the Investigator. Lower counts indicate less severe disease. (NCT03457636)
Timeframe: Baseline, Week 4, Week 8, Week 12

Interventioncount of lesions (Median)
BaselineWeek 4Week 8Week 12
Doxycycline Anhydrous and Adapalene/Benzoyl Peroxide3321126

[back to top]

Inflammatory Score

changes in inflammatory score. Minimum score is 0, maximum score is 144. Higher score indicates presence of more inflammation. (NCT05096312)
Timeframe: upon enrollment, at 4 weeks, at 8 weeks

,
Interventionscore on a scale (Median)
Initial4 weeks8 weeks
Placebo Group48.547.522.67
Zinc Gluconate Group7022.678.34

[back to top]

Global Acne Grading System Score

changes in Global Acne Grading System (GAGS) score. Minimum score is 0, maximum score is 44. Cut off scores are as follows: no lesion (0), mild (1-18), moderate (19-30), severe (31-38), and very severe (≥39) (NCT05096312)
Timeframe: upon enrollment, at 4 weeks, at 8 weeks

,
Interventionscore on a scale (Median)
Initial4 weeks8 weeks
Placebo Group30.3327.521.67
Zinc Gluconate Group3221.6714.34

[back to top]